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Introduction: Preeclampsia is a complex hypertensive disorder diagnosed during pregnancy, ≥ 20 weeks’ 
gestation. Collectively, preeclampsia and eclampsia account for one-third of severe maternal morbidities and are 
responsible for 10–15% of maternal mortality rates, predominantly in low to middle-income countries. While 
the pathogenesis of preeclampsia remains unclear, multiple studies suggest aetiology may stem from a 
combination of several complex, multifactorial interactions, including genetic and environmental causes. Few 
studies report on the global incidence or prevalence of preeclampsia, nor examine specific risk factors within 
individual nations, including Aotearoa/New Zealand. Moreover, due to reliance on now outdated diagnostic 
criteria, under-reporting of rates of preeclampsia is likely. 
Aim: This research aims to 1) describe the incidence and prevalence of preeclampsia both globally and 
nationally, and 2) identify any environmental, geographical, cultural and socio-economic factors that may be 
associated with preeclampsia incidence and prevalence in Aotearoa/New Zealand. All primary research studies 
and other relevant published literature informing the topic between January 2010 and August 2020 will be 
critiqued and evaluated; in particular, those meeting with cross-sectional, cohort or systematic review criteria.  
Method: The quantitative method of an integrative review was selected as the most suitable for an extensive 
critique and analysis of international and national literature available over the past decade which commented on 
the mapping of the global incidence and prevalence of preeclampsia, while identifying emergent themes of 
interest. Key word searches will be undertaken within the Wintec ‘OneSearch’ library access of major data 
bases, including (but not limited to) CINAHL Complete, Clinical Trials, Directory of Open Access Journals, 
Gale Academic One File, PLOS/ONE and Science Direct. Articles not relating specifically to preeclampsia 
incidence and/or prevalence will be excluded along with any duplicates, articles not available in English, and 
those involving animal rather than human participants. By assessing many forms of research, the existing body 
of knowledge can be evaluated and future areas for interest and research potential ascertained.  
Results: Following analysis of six multi-database keyword searches identifying 2833 potential articles for 
review, the search was limited to include academic journals only and studies undertaken between January 2015 
and August 2020, in order to attempt to exclude those drawing on pre-2014 diagnostic criteria for preeclampsia 
requiring manifestation of proteinuria. Once duplicates were excluded, abstracts were then analysed for potential 
inclusion. Keyword search six was abandoned due to a significant number of identified duplicates. Those 
making no specific reference to incidence or prevalence of preeclampsia were also excluded. In total, 64 studies 
from around the globe were included in the final review analysis and examined in full-text PDF format. Many 
studies published beyond 2015 continued to apply outdated diagnostic criteria for preeclampsia or failed to 
report their countries overall incidence and/or prevalence of preeclampsia. Other studies that later re-evaluated 
their findings in line with the revised 2014 International Society for the Study of Hypertension in Pregnancy 
Guidelines noted higher incidence of preeclampsia once new criteria were applied. Many studies attributed the 
incidence of preeclampsia to poverty, delayed and/or inaccurate diagnosis, limited health resources, or 
inequitable access to those that were available; however, this aspect needs further and more in-depth 
exploration. There were no studies originating from Aotearoa/New Zealand that met with inclusion criteria, 
meaning scope for future research within this context is warranted.   
Conclusion: Globally and within Aotearoa/New Zealand, incidence and prevalence of preeclampsia cannot be 
determined in exact measures, due largely to limitations in reporting, and the potential for missed diagnosis due 
to use of conflicting diagnostic criteria. Additionally, further examination and assessment of factors such as 
environmental, geographical, cultural, and social considerations which may influence and/or impact on the 
incidence and prevalence of preeclampsia, both globally and within an Aotearoa/New Zealand framework, 
should be comprehensively explored and evaluated.  
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CONSIDERATION OF ETHICS 
 
The commitment to engage with the research process is a legal prerequisite for all 
New Zealand registered midwives (New Zealand College of Midwives [NZCOM], 2015). 
Furthermore, knowledge of research methodology provides deeper insight and appreciation 
for research processes whilst simultaneously encouraging health practitioners to become 
well-informed research consumers (Whitehead & Maude, 2016).  
 
There exists no predisposed right to conduct or undertake research. Ethical and 
culturally appropriate research methods, by definition, must unfold within a framework in 
which multivalent systems both compete and conflict. Moreover, one must remain alert to the 
fact that, whenever people are recruited as research participants, an inherent risk for harm 
potentiates. Midwives, as with all healthcare professionals, need firstly to ensure any research 
proposal is morally, ethically, and culturally validated prior to commencement (Anderson & 
Thorogood, 2015).  
 
Following the post-World War II Nuremberg trials for atrocities committed against 
humanity, the inherent need to minimise risk for future harm led to the establishment of 
international research ethics guidelines; including the Nuremberg Code, the Helsinki 
Declaration, The Belmont Report and the International Ethical Guidelines for Biomedical 
Research Involving Human Subjects (Jarmusik, 2019). These research ethics guidelines, 
when aligned with our nation’s commitment to Te Tiriti ō Waitangi principles and bi-cultural 
considerations, ensure a legal framework within which advocacy for health policies that 
promote the tenants of social justice and informed choice and consent may be upheld 
(Burgess, 2008).  
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As Tangata Whēnua of Aotearoa/New Zealand, Māori have (as granted by the 1975 
Treaty of Waitangi Act and 1988 Royal Commission on Social Policy), the right to optimal 
health and wellbeing, yet are disproportionately represented in the worst of our nation’s 
social and health statistics (Ramsden, 2007; Perinatal and Maternal Mortality Review 
Committee [PMMRC], 2020). Therefore, while there is no formal requirement for ethical 
approval to be granted prior to undertaking an integrative review, Te Tiriti ō Waitangi key 
principles of self-determination, partnership, protection and participation (alongside our 
midwifery model of care and standards for professional practice)  must continue to underpin 
Aotearoa/New Zealand’s biomedical,  ethical and cultural commitment to uphold human 
rights, medical accountability, patient dignity, appropriate treatment and effective 
communication for our most vulnerable populations, in particular Māori (NZCOM, 2015; 
Waikato District Health Board [WDHB], 2020).  As such, Te Tiriti ō Waitangi provides the 
legal framework for identifying actual and potential Māori issues and ethical concerns and 







Ko Rachel Taylor toku ingoa 
Ko ahau te whaea ō nga tamahine ō te iwi ngati toa 
Kia kaha wāhine toa 




“Health is not merely the absence of disease or infirmity; it is a social phenomenon, the 
determinants of which cannot be separated from the social & cultural world in which we live”                                                                                                                                 
(Rose, 1992, as cited in Thorogood, 2015, p.59). 
 
Prior to commencing work at the Waikato Institute of Technology (Wintec) I was 
employed as a rural caseload locum midwife in the South Waikato region, one of the largest, 
most diverse and geographically remote areas in New Zealand, representing 10% of the 
national birth rate in 2014 (Waikato District Health Board [WDHB, 2015). The birthing 
population in the South Waikato communities are predominantly Māori, often living in 
poverty with poor general health. The area is flanked by dairy farms and industrial zones, 
both of which spill environmental contaminants into the waterways and soil. Many homes 
built in the 1950s in response to the need to house the influx of workers to the region (and 
destined for demolition after 5 – 10 years), remain privately tenanted and dilapidated with 
deteriorating walls coated in lead-based paint and lined with asbestos. There is high ratio of 
fast-food outlets in the South Waikato urban areas and obesity affects as many as 70% of 
women. Up to 50% of women will continue to smoke throughout their pregnancy and more 
than 50% of children live in extreme social deprivation. More of these children will be born 
small and face long-term adverse health sequelae. Additionally, it is estimated that at least 
10% of pregnant women in these areas will develop gestational diabetes mellitus and long-
term Type II diabetes mellitus, both of which engender significant risk for lifelong 
hypertensive disorders and cardiovascular disease.  The region has a higher (predominantly 
Māori) teenage birthing rate than other regions; a cohort now determined as one of the most 
at-risk pregnant populations in Aotearoa/New Zealand (Health Quality & Safety Commission 
[HQSC], 2019; WDHB, 2020). The number of young women I cared for over the years who 
suffered the consequences of preeclampsia and eclampsia (including kidney failure requiring 
transplant, severe essential hypertension, and stillbirth), is a sad yet insightful reflection on 
the preventable cycle of socio-economic deprivation and its engendered co-morbidities. 
Strong government policies that support improved and more accessible maternity and social 
services are essential in New Zealand if we are to successfully address and achieve better 
outcomes for our most vulnerable and at-risk populations.    
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CHAPTER ONE – INTRODUCTION 
 
1.1 Introduction to Preeclampsia 
Written accounts of the history of preeclampsia as a uniquely human pregnancy 
condition date back as far as 5000 years, meaning there have been approximately three – five 
billion documented cases since Homo sapiens first walked upon the Earth (Robillard et al., 
2016). According to the World Health Organisation (WHO) evaluation, preeclampsia afflicts 
approximately four million births every year, resulting in as many as 50,000 maternal deaths 
globally, the burden of which is largely carried by developing nations (WHO, 2011, as cited 
in Robillard et al., 2016).  
Emergent research over the past decade has given rise to burgeoning evidence of links 
between genetic, immunological, inflammatory, and environmental factors and the 
pathogenesis of preeclampsia (Hutcheon et al., 2011). Furthermore, current research relating 
maternal systemic inflammatory responses to a predisposition for developing preeclampsia, 
continues to draw interest from clinicians worldwide. This will likely provide impetus for 
ongoing research and further insight into the preeclampsia disease pathology (Redman & 
Staff, 2015).  
Globally, preeclampsia features as a leading cause of maternal, fetal and neonatal 
morbidity and mortality (Duley, 2009) and is associated with numerous pathophysiological 
changes leading to vascular dysfunction, and central nervous and systemic organ dysfunction; 




This introductory chapter will provide a definition of hypertensive disorders of 
pregnancy in Aotearoa/New Zealand, discuss the background and aims of this research within 
a New Zealand midwifery model of care, and assess current challenges presented by health 
inequities and barriers to health care access, in particular by Māori, as Tangata Whēnua of 
Aotearoa/New Zealand. Finally, the structure of the thesis will be explained and summarised 
prior to moving to Chapter Two, which will examine the definition of preeclampsia, define it 
in terms of both incidence and prevalence, evaluate current criteria for accurate diagnosis, 
identify risk factors for preeclampsia, and assess the aetiology and pathophysiology of 
preeclampsia. 
 
1.2 Hypertensive Disorders of Pregnancy in 
Aotearoa/New Zealand 
 
Hypertensive disorders of pregnancy (HDP) in New Zealand are classified and coded 
by the Ministry of Health (MoH, 2018) into five categories, each aligning with the revised 
2014 International Society for the Study of Hypertension in Pregnancy (ISSHP) statement to 
include:  
▪ chronic/pre-existing hypertension  
▪ gestational hypertension  
▪ pre-eclampsia  
▪ eclampsia  
▪ HELLP syndrome (a variant of severe pre-eclampsia; elements of which include 
Haemolysis, Elevated Liver enzymes, and Low Platelet count).  
12 
 
HDP are the most commonly-reported cause for medical referral arising during 
pregnancy and are the second highest cause of pregnancy-associated hospital admissions in 
Aotearoa/New Zealand, occurring in approximately 5 – 10% of all pregnancies. Preeclampsia 
is diagnosed in 3 – 8% of all pregnancies, depending on region and individual District Health 
Board data and reporting (HQSC, 2019; MoH, 2018). Furthermore, women with HDP are 
more likely to experience pregnancy complications including placental abruption, premature 
delivery, fetal growth-restriction and neonatal demise (HQSC, 2019). 
Known causes and risks for preeclampsia include genetic factors, ethnicity, 
immunologic processes, obesity (and other life-style factors), socio-economic and deprivation 
considerations, and environmental factors including pollution and geographic location, while 
in low and middle-income settings, preeclampsia and eclampsia feature in approximately 8% 
of all pregnancies, accounting additionally for 15 – 20% of all maternal morbidity and 
mortality statistics (Engjom et al., 2018). 
 
1.3 Background to this Study 
 
 In 2013, a global and regional systematic review of the estimated incidence of 
preeclampsia was published by a collaboration of Argentinian and WHO researchers in the 
Department of Reproductive Health and Research, Geneva, Switzerland, with an aim to 
assess the methodological quality of eligible studies reporting incidence on HDP between 
2002 – 2010 (Abalos et al., 2013). Preeclampsia and eclampsia have been identified as 
leading global causes of both maternal morbidity and mortality, and the reduction of maternal 
mortality is a key aim within the WHO Millennium Development Goals project, thereby 
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giving merit to the 2013 review which undertook an evaluation of the global and regional 
impacts of preeclampsia and other hypertensive disorders of pregnancy (Abalos et al., 2013). 
Of 129 studies that met with the 2013 (Abalos et al., 2013) study’s inclusion criteria, 
74 reports obtained from 78 databases reporting on HDP were analysed. Data assessed 
represented close to 39 million women from 40 nations and determined an overall global 
incidence of 4.6% for preeclampsia and 1.4% for eclampsia. Limitations of the review were 
the comparatively small number of countries reporting on preeclampsia and eclampsia, with 
only seven reporting on national incidence. Furthermore, most articles reviewed emanated 
from North America and Western European countries, meaning reporting over global regions 
was limited and incidence rates therefore difficult to determine with any certainty (Abalos et 
al., 2013). Additionally, the Abalos et al. review defined preeclampsia as new-onset 
hypertension in the second half of pregnancy, with proteinuria as a requirement for diagnosis; 
a definition that was subsequently revised in 2014 to remove proteinuria (and include fetal 
growth restriction) as a requisite feature of the disease pathology (Abalos et al., 2013; Brown 
et al., 2018; Lowe et al., 2015).  
This revised definition was then recommended for integration into New Zealand 
practice that same year, and further reinforced within the 2018 New Zealand’s Ministry of 
Health updated publication of the Diagnosis and treatment of hypertension and preeclampsia 
in pregnancy in New Zealand guidelines (MoH, 2018). Given the 2013 Abalos global review 
drew upon this now-outdated definition criteria for preeclampsia, there is likelihood that 
diagnosis, coding and/or reporting may have been inaccurate, overlooked and therefore 
unreliable, giving merit to this integrative review, as well as highlighting implications for 
future research studies within an Aotearoa/New Zealand framework and context. 
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1.4 Aims of this Research 
 
Although the pathogenesis of preeclampsia is extremely complex, multiple studies 
now suggest its aetiology may stem from a combination of several complex, multifactorial 
interactions, including genetic and environmental causes (Hutcheon et al., 2011). 
Furthermore, few studies since the 2013 systematic review (Abalos et al., 2013) have 
reported on either the global incidence or prevalence of preeclampsia, nor examined specific 
risk factors within individual nations, including Aotearoa/New Zealand. Moreover, due to 
reliance on now outdated diagnostic criteria, under-reporting of rates of preeclampsia may be 
suspected. 
This research aims to: 
1. Investigate and describe the incidence and prevalence of preeclampsia both globally 
and nationally,  
2. Identify any environmental, cultural, and socio-economic factors that may be 
associated with preeclampsia incidence and prevalence in Aotearoa/New Zealand.  
These aims will be achieved by critiquing and evaluating primary research studies and 
other published literature between January 2010 and August 2020; in particular, those 
meeting with defined inclusion criteria (see below) and which fulfil either cross-sectional, 
cohort or systematic review methodology. The quantitative method of an integrative review 
will be undertaken to critique and analyse existing international and national literature 
available over the past decade which comments on the mapping of the global incidence and 
prevalence of preeclampsia. Articles not relating specifically to preeclampsia incidence 
and/or prevalence will be excluded, along with any duplicates, articles not available in 
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English, and those involving animal rather than human participants. By assessing many forms 
of research, the existing body of knowledge can be evaluated and future areas for interest and 
research potential ascertained. Additionally, by evaluating current knowledge and 
understanding of the prevalence and incidence of preeclampsia (alongside any potential 
social and environmental influences), this research hopes to determine and identify any gaps 
in current Aotearoa/New Zealand hypertension in pregnancy guidelines to better inform 
future midwifery, maternity and health-care initiatives. 
__________________________________________________________ 
  
1.4.1 Factors for Consideration alongside the Research Aims: 
While the pathogenesis of preeclampsia remains uncertain, multiple studies now 
suggest its aetiology stems from a combination of several complex, multifactorial 
interactions; including genetic and environmental considerations (Zhou et al., 2019). 
Furthermore, given much of the information currently available regarding risk stratification 
and the management of preeclampsia emanates from predominantly high-income countries, 
there is ongoing need for further investigation in countries reporting the highest incidence of 
maternal mortality related to preeclampsia (Dias et al., 2019). Additionally, due to sub-
optimal reporting alongside inconsistent application of correct and current diagnostic criteria, 
the actual global incidence of preeclampsia is yet to be determined (Mayrink et al., 2019).  
1.4.1.1 World-wide Incidence and Prevalence of Preeclampsia and Potential Risk Factors 
World-wide incidence of preeclampsia may range anywhere from 2 – 17% (Poropet et 
al., 2018), and is responsible for 15 – 20% of severe maternal and perinatal morbidity and 
mortality cases, including 60,000 maternal deaths and more than 500,000 premature births 
each year (Ma’ayeh & Costantine, 2020), particularly in low-middle income countries (Elliot 
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et al., 2014). Incidence is estimated to be seven-times higher in developing nations such as 
India (Malik et al., 2019), while prevalence in certain Latin American countries is estimated 
to be greater than 25%, giving rise that differing rates globally may be attributed to unique 
geographic, social, economic and racial differences (Ma’ayeh & Costantine). A 2011 
Canadian study examining the epidemiology of preeclampsia and other hypertensive 
disorders of pregnancy (Hutcheon et al., 2011) reported a 3% incidence in the United States 
of America (USA), 3.3% in New Zealand (based on a 1995 prospective study undertaken by 
Stone et al., 1995) 3% in Sweden, 4.5% in Denmark and 3% in Norway. Incidence rates were 
higher in certain North American regions (8.4% in Washington State and 8.7% in Nova 
Scotia respectively; both of which correctly defined preeclampsia without the previously 
required inclusion of proteinuria). Hutcheon et al. (2011) also noted a seasonal variation of 
incidence of preeclampsia; for example, in Northern regions, incidence is more common 
amongst winter births (Finnish women report a two-fold higher risk for preeclampsia than 
women in Southern Europe), while in Zimbabwe, there is marked variance in incidence 
between the dry and wet seasons. Additionally, global prevalence amongst pregnant 
adolescents (a high-risk birthing cohort) has been determined at 6.7% (Macedo et al., 2020). 
Overall, global rates have risen on average from 0.5 – 1% (depending on location and 
available data) between 1992 and 2002 (Hutcheon et al.). 
1.4.1.2 Aotearoa/New Zealand Incidence and Prevalence of Preeclampsia and Potential Risk Factors 
In Aotearoa/New Zealand, there are growing concerns around the impact of socio-
economic disparity and health inequity amongst an ethnically diverse population (HQSC, 
2019). National rates of preeclampsia are estimated to afflict between 3 – 6% of all 
pregnancies, resulting in multi-system pathologies and poor maternal, fetal and new-born 
outcomes (Mirzakhani et al., 2016).   
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1.4.1.3 Harm Potential of Preeclampsia for Women & Babies 
Risks to women afflicted with preeclampsia include convulsions, placental abruption, 
cerebral haemorrhage and disseminated intravascular coagulation, renal failure and 
subcapsular liver haemorrhage, with increased risk for depression, cardiovascular disease and 
stroke in later life (Tanaka et al., 2007).  
Risks for babies include growth restriction, oxidative stress, neonatal acidosis and 
hypoxaemia, neonatal encephalopathy, pre-term birth and death (Duley, 2009). Considering 
that each case of neonatal encephalopathy costs New Zealand taxpayers $55 million dollars 
(HQSC, 2019), meticulous antepartum care that includes early recognition and timely 
intervention for high-risk women is required alongside appropriate postpartum care.  
Such undertaking will increase likelihood that early warning signs will not be missed, 
and that ongoing preeclampsia care and management strategies in Aotearoa/New Zealand are 
improved and enhanced. 
 
1.5 Midwifery Model of Care in Aotearoa/New Zealand 
  
Current incidence of preeclampsia in Aotearoa/New Zealand is estimated to affect 3 – 
6% of all pregnancies (Mirzakhani et al., 2016) and may potentially be influenced by various 
environmental and socio-economic considerations as yet to be fully explored and 
investigated. Our country’s unique model of midwifery and maternity care (based upon the 
tenants of partnership and continuity of care) may afford an appropriate pathway to explore 
the aims of this research in its commitment to maternity care provision that engages directly 
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with all women across a culturally diverse and often challenging primary-tertiary healthcare 
interface.  
Midwifery care in Aotearoa/New Zealand is an autonomous practice that became an 
independent and registered health profession following the 1990 Nurses’ Amendment Act 
(NZCOM, 2015). Following enaction of the 2003 Health Practitioners’ Competency 
Assurance Act, midwifery has been regulated by the Midwifery Council of New Zealand 
(MCNZ) since 2004 (MCNZ, 2019). Alongside MCNZ competencies, midwifery standards 
for professional practice are determined by NZCOM, and placed in equal partnership 
alongside the profession’s cultural competency framework of Turanga Kaupapa, gifted to the 
College in 2008 by the Māori midwifery collective, Ngā Maia (Ngā Maia 2006, as cited in 
NZCOM, 2015). 
The term ‘midwife’ translates literally as ‘with woman’ and, in Aotearoa/New 
Zealand is an autonomous profession synonymous with the political struggles of the 
consumer-led feminist movement; the ‘Save the Midwife’ campaign, launched in the late 
1970s by a “vociferous minority” of women intent on preserving their birth rites (and rights) 
against the encroaching tide of medicalised childbirth (Donley, 1992, p. 1). Midwifery, as a 
dynamic art as well as a science, is founded upon a collection of knowledge derived not only 
from research, obstetrics and associated health sciences, but from the lived experiences and 
stories of women; including their herstory and philosophies placed alongside feminist theory, 
biculturalism, and the cultural frameworks within which this is grounded (NZCOM, 2015; 
Wintec, 2017, p. 4).  Furthermore, as a holistic profession, the social, emotional, physical, 
spiritual, cultural and psychological ramifications of women’s health experiences must be 
considered throughout the continuum of the midwifery partnership; seeking actively to 
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uphold, protect and promote women and their babies’ wellness, alongside facilitation of 
understanding of these key issues within the wider community (NZCOM, 2015). 
 
Midwives in Aotearoa/New Zealand are professionally responsible for the provision 
of all care, support and advice given to women and their families throughout the pregnancy, 
childbirth and labour, and up to six weeks’ postnatally. They facilitate and support the 
physiological birthing process, identify any complications that may arise at any time in both 
or either mother and baby, ensure access to appropriate services, provide emergency care and 
assistance if required, as well as ensure and oversee all neonatal cares, breastfeeding 
education and assistance. If, at any time, a woman requires urgent or non-urgent referral for 
secondary and/or tertiary health care, New Zealand midwives do so in collaboration with 
other health professionals and associated providers. Additionally, and in accordance with key 
objectives of Section 88 of the Primary Maternity Services Notice 2007, they may practice in 
any setting, including the home, hospital or community and are fully responsible and 
accountable for the care they provide, as per the Midwifery Scope of Practice and 
Competencies as defined by the MCNZ (MCNZ, 2019). Furthermore, this care must be 
founded on Te Tiriti ō Waitangi principles which advocate for policies promoting social 
justice and informed choice and consent (NZCOM, 2015). 
 
Midwifery, therefore, by its very definition, must take place in partnership with 
women, working within a framework that embraces continuity of care to both enhance and 
protect the normal physiological processes of pregnancy, childbirth and the postpartum 
period (NZCOM, 2015). As previously mentioned, the concept of partnership embraced by 
the profession expands far beyond that which exists simply between midwife, wāhine 
(woman) and whānau (family); our recognition and commitment to the legal relationship 
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we uphold as a bicultural nation incorporates both Te Tiriti ō Waitangi and Turanga 
Kaupapa principles which are integral to midwifery professional standards and competencies 
for practice (Guilliland & Pairman, 1995; NZCOM, 2015; MCNZ, 2019).  
 
The Turanga Kaupapa cultural framework and guidelines serve to enhance 
Ngā Maia Kaupapa and provide cultural competencies for midwifery care in Aotearoa/New 
Zealand, founded upon the four key Te Tiriti ō Waitangi principles as developed by the Royal 
Commission on Social Policy in 1988 (Hikuroa & Halliday, 2013). These fundamental 
tenants underpin Turanga Kaupapa and serve to strengthen our commitment as health 
practitioners to redress social and gender inequity and provide the women of New 
Zealand with a model of midwifery care that embraces inclusive practice, self-determination, 
empowerment and respect (NZCOM 2015; MCNZ, 2019; Ramsden, 2007).  
 
Turanga Kaupapa   
Whakapapa: The wāhine and her whānau is acknowledged  
Karakia: The wāhine and her whānau may use karakia  
Whanaungatanga: The wāhine and her whānau may involve others in her birthing programme  
Te Reo Māori: The wāhine and her whānau may speak Te Reo Māori  
Mana: The dignity of the wāhine, her whānau, the midwife and others involved is maintained  
Hau Ora: The physical, spiritual, emotional and mental wellbeing of the wāhine and her whānau is 
promoted and maintained  
Tikanga Whēnua: Maintains the continuous relationship to land, life and nourishment; and the 
knowledge and support of kaumatua and whānau is available  
Te Whāre Tangata: The wāhine is acknowledged, protected, nurtured and respected as Te Whāre 
Tangata (the “House of the People”)  
Mokopuna: The mokopuna is unique, cared for and inherits the future, a healthy environment, wai 
ū and whānau  
Manaakitanga: The midwife is a key person with a clear role and shares with the wāhine and her 
whānau the goal of a safe, healthy, birthing outcome  
 




Thanks to strong professional adherence to these prerequisites (NZCOM, 2015; 
MCNZ, 2018), midwifery and midwifery education must, by proxy, reflect these key Treaty 
concepts alongside Turanga Kaupapa and social justice. These concepts are in close 
alignment with social reconstruction ideology, within which the purpose is to facilitate the 
redress of all racial, gender, social and economic inequalities (Schiro, 2013). The very heart 
of midwifery must therefore continue to embrace the fundamental partnership between 
woman and midwife alongside our professional commitment to honour bi-
culturalism, improved health outcomes, equity, and literacy for all (Wintec, 2017, pp. 3-4).  
Given that a primary aim of this research is to explore any potential environmental, 
cultural, and socio-economic factors that may be associated with preeclampsia incidence and 
prevalence in Aotearoa/New Zealand, our unique model of midwifery care is particularly 
well-suited to exploring these, given our privileged position of working directly and 
intimately with women, their babies, and families throughout their entire pregnancy, birthing 
and postpartum journey. 
 
1.6 Health Inequity in Aotearoa/New Zealand 
 
For midwives and health educators, the social determinants of health disparities and 
outcomes cannot be ignored. In June 2018, Dr Terry-Ann Clarke (keynote speaker 
and Māori advisor to the Ministry of Health) delivered a powerful message before the annual 
PMMRC in the form of her proposed Māori health rubric for addressing health inequity in 
Aotearoa/New Zealand. It is imperative moving forward that New Zealand health providers 
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and midwives continue to develop culturally responsible and responsive approaches and 
methodologies that will address these fundamental concerns.  
 
Dr Clarke’s rubric commits to upholding three simple key goals:  
 
▪ Tika – we address the needs of the people and interpret these needs correctly.  
▪ Mana – we advance equity, self-determination and social justice.  
▪ Mahi tahi – we establish relationships for positive change.   
(Clarke, 2018).  
These three goals align and interweave synergistically with Turanga Kaupapa and Te 
Tiriti ō Waitangi principles that serve as both reference and guidance for midwives in 
Aotearoa/New Zealand to engage positively with women and their families for improved 
health outcomes within the wider community (NZCOM, 2015). Additionally, these key areas 
support a primary aim of this research to explore and determine any potential environmental, 
cultural, and socio-economic factors that may influence preeclampsia incidence and 
prevalence within Aotearoa/New Zealand. 
In New Zealand, Māori and Pacific peoples currently experience greater challenges in 
achieving improved health outcomes due to poverty, discrimination, and poor access to 
appropriate and culturally responsive care. Māori women have the lowest uptake of first 
trimester maternity services and are less likely to receive acceptable levels of care despite 
clinical and medical indication (HQSC, 2019). 
Furthermore, maternal and perinatal-related mortality rates vary significantly in New 
Zealand when the Index of Deprivation 2013 quintile categories are considered and applied; 
of particular concern are statistics involving babies of women living in the most deprived 
social circumstances and regions (quintile five), who experience far greater mortality rates 
than any other, with variation in mortality by scale of deprivation most noted in neonatal 
demise due to spontaneous premature birth, with mortality risk and incidence increasing 
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exponentially alongside increasing deprivation (PMMRC, 2019). In turn, deprivation deciles 
consider the distribution of deprivation throughout Aotearoa/New Zealand, and divide the 
country’s population into ten parts, with 10% of the population represented in each one. For 
babies born to New Zealand European women, approximately 10% are represented each 
decile; however, for Maori, there are very few babies born into the higher deciles, and more 
than half are born into the most deprived deciles (8 – 10), proving a marked increased risk for 
deprivation amongst babies born to Māori mothers, with any baby born into a decile ten area 
experiencing the highest rate and risk of mortality. Furthermore, Māori are the most 
disproportionately affected population in New Zealand when considering the impact and 
burden of perinatal-related mortality alongside decile ratings, experiencing nearly twice as 
many deaths in this group than any other (PMMRC).  
As such, research that seeks to identify trends and causes in health inequity for New 
Zealand’s most vulnerable populations (with an aim to determine if modifiable factors such 
as environmental, geographical, cultural, and socio-economic considerations negatively 
impact current rates of preeclampsia) is overdue and warranted. 
 
1.7 Structure of the Thesis 
 
Chapter One has provided the context for this thesis aim, has defined and described 
the categories of hypertensive disorders of pregnancy in Aotearoa/New Zealand, discussed 
the background and aims of this research framed within the New Zealand midwifery model of 
care, and assessed current challenges presented by health inequities and barriers to health care 
access, in particular by Māori, as Tangata Whēnua of Aotearoa/New Zealand. 
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Chapter Two will explore and examine the current and revised definition of 
preeclampsia, define the disorder in terms of both incidence and prevalence, evaluate current 
criteria for accurate diagnosis, assess risk factors for preeclampsia and, finally, review the 
aetiology and pathophysiology of preeclampsia. 
Chapter Three will briefly revisit the aim of the thesis and present the method by 
which the literature informing the incidence and prevalence of preeclampsia will be explored 
both globally and within Aotearoa/New Zealand, alongside considerations for any relevant 
environmental, cultural, and socio-economic factors. The integrative review method will be 
described and evaluated to explain the process of the literature search, analysis, and synthesis 
of the selected literature which will then be more closely scrutinised in subsequent chapters.   
Chapter Four will synthesise and further evaluate both global as well as national 
incidence and prevalence of preeclampsia in Aotearoa/New Zealand and provide comment 
upon emergent themes of interest that may impact upon future practice and research 
opportunities. Additionally, it will briefly highlight any noted limitations of the research 
which may then be drawn upon to inform areas for future study and inquiry in Chapter Five.  
Chapter Five will summarise the main findings of the integrative review, provide 
discussion on emergent themes and limitations captured during the review process, discuss 
key conclusions drawn by the thesis and provide advice regarding implications for future 







This chapter has examined the current definition of hypertensive disorders of 
pregnancy in Aotearoa/New Zealand and discussed the background and aims of this study 
within a New Zealand midwifery model of care, while assessing current challenges presented 
by health inequities and barriers to health care access, particularly for Māori, as Tangata 
Whēnua of Aotearoa/New Zealand. The validity of the research aims has been established 
and the structure for the thesis discussed and summarised by way of introduction to 





CHAPTER TWO - PREECLAMPSIA 
 
2.1 Introduction 
This chapter will explore the current and revised 2014 definition of preeclampsia, 
define preeclampsia in terms of its incidence and prevalence, evaluate current criteria for 
accurate diagnosis, assess known risk factors for the prediction of preeclampsia, and review 
the aetiology and pathophysiology of preeclampsia as a hypertensive disorder of pregnancy. 
 
2.2 Definition of Preeclampsia 
 Pregnancy is essentially a vasodilatory state, during which there is an 8 to 10-fold 
increase in the vasodilator prostacyclin (Karumanchi et al., 2005). During the progression of 
a ‘normal’ pregnancy, blood pressure will begin to fall from the first trimester, generally 
reaching its lowest reading in the second trimester, then rising to pre-conceptual levels by 
term (Lowe et al., 2015). 
With the hypertensive disorder preeclampsia, these normal pregnancy changes are 
altered or disrupted …                                                                                           
(Lowe et al., 2015). 
 
The 2014 Society of Obstetric Medicine of Australia and New Zealand (SOMANZ) 
Guideline on Hypertensive Disorders of Pregnancy defined gestational hypertension as a 
systolic blood pressure of greater or equal to 140mmHg and/or a diastolic blood pressure 
greater or equal to 90mmHg arising at or beyond 20 weeks’ gestation (Lowe et al., 2015).  
In 2018, the New Zealand MoH (MoH, 2018) adopted this definition in line with the 
2014 revised ISSHP statement, and included consideration for chronic/pre-existing 
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hypertension, gestational hypertension, preeclampsia (either newly occurring (de novo) or 
superimposed on chronic hypertension, eclampsia and HELLP syndrome (now considered as 
a severe manifestation of preeclampsia) (Brown et al., 2018). 
Preeclampsia, therefore, may be defined as a unique multi-organ pregnancy 
hypertensive disorder characterised by gestational or pre-existing hypertension and 
involvement of one or more other organ systems that may include placental dysfunction 
and/or the fetus. While it is important to note that hypertension (as defined above) is a 
common feature of preeclampsia (and additionally that an increase in baseline of 30 mmHg 
systolic or 15 mmHg diastolic may also be of clinical importance), an increase in blood 
pressure may not necessarily present as the initial feature of the disease pathology. 
Furthermore, proteinuria (previously used to elicit diagnosis of preeclampsia), is no longer a 
mandatory part of the diagnostic criteria for either preeclampsia or HELLP syndrome (Lowe 
et al. 2015; MoH, 2018).  
2.2.1 Proteinuria 
While proteinuria is no longer part of the diagnostic criteria for evaluation of 
preeclampsia, preeclampsia nonetheless remains the most common cause of severe 
proteinuria in pregnant women (August & Sibai, 2020). Proteinuria occurs secondary to 
impaired integrity of the glomerular barrier and altered tubular handling of filtered proteins 
(hypofiltration) leading to increased protein excretion (Norwitz & Repke, 2020). However, 
several clinical studies cited in Lowe et al. (2015) have demonstrated that neither the rate of 
increase nor the amount of proteinuria affects maternal or perinatal outcomes in the 
pathophysiology of preeclampsia, meaning repeated 24-hour urinary protein estimations are 
not useful. Once the threshold of 0.3g/24 hours or a protein/creatinine ratio (PCR) ≥30 is 
determined, repeated urinary PCR testing is both unnecessary and burdensome to the health 
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dollar. Furthermore, fetal growth restriction should be recognised early and managed 
appropriately, regardless of whether preeclampsia is formally diagnosed (Lowe et al., 2015). 
However, as many studies beyond 2014 continue to cite proteinuria as a critical element, 
exact rates of preeclampsia incidence and prevalence are likely to be inaccurately diagnosed, 
coded and reported. 
 
2.2.2 Haemolytic Anaemia, Elevated Liver Enzymes & Low Platelets 
 ‘HELLP’ Syndrome 
HELLP may represent a severe form of preeclampsia, but the relationship between the 
two disorders remains controversial. While incidence is rare (approximately 0.1 – 0.8% of all 
pregnancies), 10 – 20% of those women with preeclampsia and/or eclampsia will develop the 
disease pathology. As 15 – 20% of women with HELLP syndrome will have no history of 
hypertension or proteinuria, some authorities have suggested it may be a separate disorder; 
however, it is generally accepted as a feature of the severe spectrum of the pathology (Sibai, 
2020). 
HELLP is associated with significant maternal and neonatal morbidity and mortality 
rates alongside its life-threatening risk for DIC, acute renal failure, pulmonary oedema and 
subcapsular liver haematoma (Blackburn, 2013). Although the exact pathology of the 
condition remains unclear, several contributing factors (including placental failure and 
immunological intolerance (between mother and baby)) are suspected (Thorogood & 
Donaldson, 2015). A 2012 (Anderson et al., 2012) cohort study on the impact of maternal 
body mass index (BMI) found that 34% of 178 pre-eclamptic women were obese (BMI>30) 
and were more likely to develop the disease pathology both in early and term pregnancy.  
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Increased BMI and risk for preeclamptic disorders can therefore be directly correlated 
as pro-inflammatory co-morbidities (Anderson et al., 2012). The key concern for health 
professionals regarding early recognition and appropriate management of HELLP is 
prevention of its associated risk for placental abruption and subsequent fetal demise (Sibai, 
2020). 
 
2.3 Definition of ‘Incidence’ & ‘Prevalence’ 
 
2.3.1 Incidence 
‘Incidence’ as a term, describes the rate of development of a disease within an 
identified cohort over a period (including its continuation and as well as any manifestation of 





In contrast, ‘prevalence’ refers to the proportion identified as having the disorder at 
any one point in time by examining the relationship between the disease and other variables 
of interest (Friedman, 2004).  
 
For the purpose of this review, both incidence and prevalence were assessed in order 




2.4 Clinical Diagnosis of Preeclampsia 
 
 A diagnosis of preeclampsia can be made when hypertension manifests after 20 
weeks’ gestation, along with one or more of the following signs: 
▪ Renal involvement including but not limited to significant proteinuria; typically, a 
urinary protein/creatinine ratio ≥30mg/mmol. This may be accompanied with rising 
serum creatine levels >90 μmol/L and potentially, oliguria <80mL over four hours. In 
the absence of proteinuria or other evidence of renal involvement, any other feature of 
end-organ damage alongside new-onset hypertension ≥20 weeks’ gestation will also 
confirm suspicion for preeclampsia. 
▪ Haematological and liver involvement including thrombocytopenia <100,000 /µL, red 
cell haemolysis, raised serum transaminases and liver necrosis, severe epigastric and/or 
right upper quadrant pain, increased levels of serum bilirubin and lactate dehydrogenase 
and, in severe cases, may include ‘HELLP’ syndrome which may precipitate 
disseminated intravascular coagulation (DIC) and uncontrolled haemorrhage. 
 
▪ Neurologically, women may present with hyperreflexia with persistent clonus, severe 
headache that fails to resolve despite analgesia, visual disturbances, eclamptic seizure 
and stroke. They may also develop pulmonary oedema, which can prove fatal. 
 
▪ Additionally, the placenta may be severely impaired and dysfunctional, typically noted 
alongside early or late-onset fetal growth restriction (Lowe et al., 2015; Malik et al., 
2019; MoH, 2018). 
 
2.5 Risk Factors for Preeclampsia 
  
A prospective multicentre cohort study undertaken in 2011 found inherent clinical 
risk factors for preeclampsia included nulliparity, advanced maternal age, hypertension, 
obesity, family history of preeclampsia and heart disease, low maternal birth weight, 
and history of antepartum bleeding (North et al., 2011). And, while preeclampsia manifests 
typically in the primiparous population, its occurrence is also significant amongst 
multigravidas pregnant to new partners, suggesting that prior exposure to paternal antibodies 
is an important protective consideration (Karumanchi et al., 2005). 
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2.5.1 Other important risk factors for preeclampsia and eclampsia: 
The New Zealand MoH Diagnosis and treatment of hypertension and preeclampsia in 
pregnancy in New Zealand guidelines (2018) additionally include an extensive list of risk 
factors for developing preeclampsia, including previous history of preeclampsia, assisted 
reproductive technology (oocyte donation), renal disease, chronic hypertension, previous 
history of HELLP syndrome, pre-existing diabetes, antiphospholipid antibodies, systemic 
lupus erythematosus, and family history of preeclampsia in either a mother or sister (MoH, 
2018). Hydatiform moles and/or molar pregnancy have also been identified as presenting an 
additional potential risk factor for development of preeclampsia (Malik et al., 2019), while 
researchers in 2017 determined evidence for the protective properties of dietary nitrates, 




2.5.2 Table 1 – Increased risk of developing preeclampsia if woman has pre-
existing risk factors 
Notable risk factors for preeclampsia: 
Pre-existing risk factor Relative risk/odds ratio 95% CI Notes 
Antiphospholipid antibodies/SLE* 9.72 4.34-21.75 MRF* 
Previous history of preeclampsia 7.19 5.85-8.83 MRF 
ART* (oocyte donation) 4.34 3.10-6.06 MRF 
Renal disease 4.07 2.17-7.66 MRF 
Chronic hypertension 3.6 2.0-6.6 MRF 
Previous history of HELLP 3.7 0.9-16.1 MRF 
Pre-existing diabetes 3.56 2.54-4.99 MRF 

















Nulliparity 2.91 1.28-6.61  
Multiple pregnancy 2.93 2.04-4.21  
Family history of preeclampsia 






Change in partner 2.5 1.8-3.5  
Elevated BMI ≥35 (early/pre-pregnancy) 2.47 1.78-3.15  
Maternal age ≥40 (multiparous) 1.96 1.34-2.87  
Maternal age ≥40 (primiparous) 1.68 1.23-2.29  
Pregnancy interval >10 years 1.83 1.72-1.94  
ART* sperm donation 1.63 1.36-1.95  
Diastolic BP ≥80mmHg at booking 1.38 1.01-1.87  
Any ART* 1.17 1.10-1.24  
 
Note: This table was adapted using statistics obtained from the New Zealand MoH Diagnosis and treatment of 
hypertension and preeclampsia in New Zealand guidelines (MoH, 2018). 
 
__________________________________________________________________________________________ 
Adjusted odds ratio and relative risk data obtained from Duckitt and Harrington (2005), as cited in MoH, 2018. 
*ART = assisted reproductive technology; BMI = body mass index; BP = blood pressure; CI = confidence 
interval; HELLP = Haemolysis, Elevated Liver Enzymes and Low Platelet count; MRF = major risk factor; SLE 
= systemic lupus erythematosus  
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2.6 Aetiology & Pathophysiology of Preeclampsia 
 
Throughout the course of a healthy pregnancy, gas, nutrient and waste product 
exchange and removal between maternal and fetal circulation is dependent on well-
functioning placental perfusion (Karumanchi et al., 2005). During the process of normal 
vascular invasion and placentation, invasive cytotrophoblasts of fetal origin enter the 
maternal spiral arteries, transforming them into high-calibre vessels capable of providing 
adequate perfusion for the developing embryo. The cytotrophoblast cells then differentiate 
from an epithelial to an endothelial phenotype, during a phenomenon known as 
pseudovasculogenesis. With preeclampsia however, cytotrophoblast cells fail to adopt an 
invasive endothelial phenotype, leading ultimately to placental ischaemia and fetal growth 
restriction (Brennan et al., 2013). 
Impaired endothelial dysfunction is central to the risk associated with preeclampsia 
and is believed to be instigated by circulating factors released following placental 
ischaemia/hypoxia. Amongst these, an imbalance in pro- and anti-angiogenic factors and 
activation of immune mediators contributing to excessive inflammation are of relevance. In 
addition, the generation of reactive oxygen species (ROS) within the endothelium plays an 
important role in vascular dysfunction. Maternal endothelial dysfunction leads to increased 
systemic resistance, which reduces perfusion to all organs including the placenta, further 
exacerbating placental ischaemia and promoting a destructive cycle. Most symptoms of the 
disease pathology of preeclampsia, including HELLP syndrome, can now be definitively 




Additionally, intrauterine fetal growth restriction (IUGR) is a key marker in the 
diagnosis of preeclampsia and presently affects approximately 5% of all pregnancies (ISSHP, 
2014). IUGR is associated with numerous short and long-term adverse outcomes, including 
the complications that iatrogenic prematurity (as a side-effect of early labour induction) may 
present for new-born babies and their mothers alike. While there are numerous factors that 
increase the risk for IUGR (including smoking, high blood pressure, IVF pregnancy, 
preeclampsia and HELLP syndrome), abnormal placentation is now considered as key to the 
pathophysiology of ‘placental’ or early-onset preeclampsia (Enkhmaa et al., 2016). 
As maternal systemic endothelial dysfunction accounts for many of the pathological 
markers of preeclampsia, minimum diagnostics should include full blood count including 
platelets, serum creatinine, aspartate aminotransferase (AST) and/or alanine aminotransferase 
(ALT), urinary protein:creatinine ratio and formal obstetric ultrasound assessment (Norwitz 
& Repke, 2020). While in Aotearoa/New Zealand we generally investigate ALT levels in 
addition to AST, the advantage to AST is that it is a single test that reflects both 
hepatocellular necrosis as well as red cell haemolysis (Sibai, 2020). Additionally, a rising 
serum haematocrit can indicate haemoconcentration (suggesting contraction of intravascular 
volume and progression to more severe disease manifestation), while a falling haematocrit 
may be a sign of haemolysis. Furthermore, while an elevated serum indirect bilirubin 
concentration may be a better marker of red cell haemolysis, an elevated lactate 
dehydrogenase (LDH) can also determine severity of the disease pathology, including the 






2.7 Important Differentiations between Early and 
Late-Onset Preeclampsia 
 
2.7.1 Definition of Early-Onset Preeclampsia 
Early-onset preeclampsia (EOP) is commonly defined as disease manifestation prior 
to 34 weeks’ gestation, frequently aligned with severe fetal growth restriction and is 
considered ‘placental’ in causation (Redmann & Staff, 2015). Placental ischaemia is 
commonly noted with early-onset preeclampsia, which in turn is associated with placental 
production of numerous inflammatory circulating factors leading ultimately to systemic 
maternal endothelial dysfunction (Brennan et al., 2013). EOP therefore appears to result from 
inadequate trophoblast and placental implantation and occurs in 30% of all documented cases 
worldwide (Robillard, 2017). 
With ‘placental’ preeclampsia, suboptimal perfusion is believed to be initiated by 
insufficient trophoblastic invasion of the uterine spiral arteries in early pregnancy, a process 
that may be addressed with the simple inclusion of low-dose aspirin and calcium 
supplementation from as early as 11 weeks’ gestation and preferably prior to 20 weeks’ 
gestation (Meher et al., 2017; Roberge et al., 2017). Malperfusion leads to placental 
ischaemia and the release of cytokines and other antiangiogenic agents which, in turn, initiate 
maternal endothelial cell activation. 
2.7.2 Definition of Late-Onset Preeclampsia 
Late-onset preeclampsia (LOP) occurs at term, from 37 weeks’ onwards. The 
intermediate onset of the disease between these times is likely a mixture of the two (Yung et 
al., 2014). Recent studies support that LOP may be classified (in terms of its 
pathophysiology) as ‘maternal’ causation, often due to pre-existing conditions such as obesity 
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and diabetes. LOP is the predominant form of preeclampsia globally (90% of all reported 
cases), particularly in developed nations where both the means and ability to undertake and 
publish research are available (Robillard, 2017). 
However, while both EOP and LOP result in varying degrees of placental 
malperfusion (Redmann & Sargent, 2007, as cited in Robillard et al., 2017), given 
preeclampsia manifests in both molar and ectopic pregnancies, neither the fetus nor uterus 
can be considered as uniquely significant contributors (Hung & Burton, 2006, as cited in 




This chapter has explored the 2014 revised and updated definition of preeclampsia, 
defined preeclampsia in terms of its incidence and prevalence, and evaluated current criteria 
for accurate diagnosis of preeclampsia. Additionally, it has assessed predetermined and 
known risk factors for the prediction of preeclampsia and reviewed both the aetiology and 
pathophysiology of preeclampsia as a hypertensive disorder of pregnancy. 
Chapter Three will again revisit the aim of the research and present the method by 
which the research will explore the literature informing the incidence and prevalence of 
preeclampsia both globally and within Aotearoa/New Zealand. The integrative review 
method will be described to explain the process of literature analysis, synthesis and 




CHAPTER THREE – RESEARCH 
METHOD: An Integrative Review 
While all research generates evidence, not all evidence is necessarily robust ...  
(Shields & Smyth, 2016). 
 
3.1 Introduction 
As previously described, the aim of this research is to 1) describe the incidence and 
prevalence of preeclampsia both globally and nationally, and 2) identify any environmental, 
cultural, and socio-economic factors which may be associated with preeclampsia incidence 
and prevalence in Aotearoa/New Zealand.  
By drawing upon an integrative review study design method, this research also aims 
to determine whether there has been a research review undertaken in the past decade of the 
geographical incidence of preeclampsia within Aotearoa/New Zealand.  
To achieve these aims, a rigorous integrative review will be undertaken in order to 
both critique and analyse all current and existing international and national literature, namely 
primary research studies and other relevant published literature which inform this study’s 
research aims between January 2010 and August 2020; in particular, those meeting with 
cross-sectional, cohort or systematic review criteria. Key word searches will be undertaken 
within the Wintec ‘OneSearch’ library access of major data bases. Any articles not relating 
specifically to preeclampsia incidence and/or prevalence will be excluded along with any 
duplicates, articles not available in English, and those involving animal rather than human 
participants. By assessing many forms of research, the existing body of knowledge can be 
further scrutinised and evaluated and future areas for interest and research potential 
determined. This section on research methodology will also describe and evaluate the process 
required to search, review and synthesis the selected literature. 
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Much of what we know and identify as quantitative research methods have been 
developed from the discipline of epidemiology, championed as early as the mid-19th century 
by Florence Nightingale when she developed statistical tests which were then used to produce 
evidence regarding outcomes for sick and wounded soldiers during the Crimean War (Shields 
& Smyth, 2016). Modern epidemiology (drawn from the Greek word meaning ‘the study of 
people) involves the study of health-related events including pathophysiology and disease 
patterns amongst human populations and aims, essentially, to achieve three goals (Shields & 
Smythe, 2016): 
1.   Identify and describe disease patterns 
2.   Identify the cause(s) of these disease patterns (aetiology) 
3.   Provide data that will then be examined and disseminated in order to inform ongoing 
and/or future management, evaluation and service-planning for the prevention, control 
and treatment of the pathology (Shields & Smyth, 2016). 
  
Quantitative or structured research methodology has its roots in the philosophy of 
rationalism and adheres to a structured and pre-determined set of procedures to explore data 
to quantify an objective and transparent result that is generalisable and will hold rigour to 
scrutiny (Kumar, 2014). 
 
3.2 The Evidence Pyramid 
 
The evidence pyramid is a useful, visual tool by which the rigour of quantitative 
research may be assessed according to its methodology. The highest (and therefore strongest) 
level of evidence includes systematic reviews, meta-analyses and critical appraisals. The 
integrative review, while not positioned at the very top of the pyramid, is a well-used 
approach to undertaking meta-analysis that does not wish to be limited to inclusion of only 
one type of study (Glover et al., 2006). While a common research approach, there are few 
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integrative reviews undertaken within the field of midwifery, meaning scope for inquiry 
using this method is warranted as an appropriate design by which to evaluate this study’s 
research question. 
 
(Glover et al., 2006). 
To enhance, develop and promote better and improved health and maternity services 
throughout Aotearoa/New Zealand, it is vital that best-evidence practice is incorporated 
within our autonomous model of midwifery care. The integrative review is one of the more 
academically rigorous methods to ensure this aim, as it requires collection, inclusion, and 
examination of all current, existing research evidence, which is then systematically critiqued 
and extensively evaluated (Shields & Smyth, 2016). Given the very nature of an integrative 
review signals inclusivity, both qualitative and quantitative research can be examined in a 
purposeful and systematic way, affording an enhanced exploration of the research aim(s). The 
integrative review process affords a theoretical background to the investigative research 
proposed by linking that which has already been studied with that which is to be examined. 
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Additionally, it cements and establishes the level of expertise in the field of interest as 
expected and helps to ground emergent areas of interest and study within the existing body of 
knowledge (Kumar, 2014). The integrative review sits within the top frame of the evidence 
pyramid and affords deeper and critical appraisal of the subject analysis and evidence 
synthesis by aiming to summarise past research, while evaluating overall conclusions drawn 
from the available and current body of literature (Whitehead & Maude, 2016).  
 
3.3 The Integrative Review Method – A Definition 
 
The integrative review method affords inclusion of studies with diverse 
methodologies to be assessed and examined in detail, as all studies that may address either 
related or identical research questions may potentially be included in the final body of 
literature (Whitehead & Maude, 2016).   
According to Whittemore and Knafl (2005), the integrative review is the only 
research approach which affords examination of a combination of diverse methodologies, 
thereby presenting strong potential to inform evidence-based practice in the realm of 
midwifery research. However, while strategies to enhance data collection and extraction are 
well developed within the method design, methods of analysis, synthesis, and conclusion 
drawing may be potentially not as robust when compared with the method of a systematic 
review incorporating meta-analysis.  
For the purpose of this research and, in order to be afforded the opportunity to 
evaluate as much data and journal articles as possible, the method of an integrative review 
was selected as the most suitable, due to its potential to allow diverse and holistic primary 
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research methods to play a greater role within evidence-based practice initiatives 
(Whittemore & Knafl, 2005). 
Whittemore and Knafl (2005) describe the integrative literature review as “a modified 
framework for research … (in order) to address issues specific to the integrative review 
method” (p. 546). Their design calls for specification of the review purpose, a comprehensive 
review of the available literature and evaluation of data from primary sources that is then 
analysed, results presented and finally discussed (Whittemore & Knufl, 2005). 
There are very few integrative reviews published to date that have focused on the field 
of preeclampsia, and even less so within a midwifery research context. Furthermore, there is 
no evidence of one having previously been undertaken within Aotearoa/New Zealand. In 
recognition of this recognised deficit, the integrative review method has been evaluated as an 
appropriately robust and suitable design for the completion of this research, with the aim that 





3.4 Review Objectives 
 
The objective of this integrative review is to evaluate and present the best available 
evidence in order to explore the following research questions: 
▪ What is the incidence and prevalence of preeclampsia both globally and within 
Aotearoa/New Zealand? 
▪ Is there potential for further exploration of the environmental, cultural and 
social/socio-economic factors that influence and/or impact on the incidence and 
prevalence of preeclampsia within an Aotearoa/New Zealand framework? 
 
3.5 Review Method 
 
“An integrative review is a specific review method that summarizes past empirical or 
theoretical literature to provide a more comprehensive understanding of a particular 
phenomenon or healthcare problem ...”                                                           
(Whittemore & Knafl, 2005, p. 546). 
 
 
As described in Chapter One, the aim of the following integrative review is to explore 
the global and national incidence of preeclampsia and evaluate any environmental, cultural 
and/or social factors that may influence prevalence of the disorder in Aotearoa/New Zealand.  
 
An integrative review seeks to synthesise all relevant and pertinent literature available 
on a particular topic, with the view to stimulate new perspectives and impetus for further 
research (Ferrero et al., 2016; Torraco, 2016). As there are few published with a specific 
midwifery focus, those that are may be cited and drawn upon by research scholars across the 
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national and international scope (Torraco, 2016). Having identified that the last 
comprehensive review of global incidence and prevalence of preeclampsia was conducted in 
2013 (Abalos et al., 2013), there is merit in revisiting this topic. Furthermore, given the 2013 
review drew upon (now defunct) diagnostic criteria for preeclampsia requiring inclusion of 
proteinuria, reliable reporting of its incidence and prevalence are likely inaccurate. Future 
investigation of other emergent and possible causes of preeclampsia is also warranted.  
 
3.6 Inclusion Criteria & Search Strategy 
 
To comply with the requirements of an integrative review study design and method 
meeting with quantitative evaluation, primary research studies and other relevant published 
information informing the topic were examined, having met firstly with broad appraisal for 
meeting with either cross-sectional, cohort or systematic review criteria. Critical analysis and 
oversight of the selected published research affords identification of both the strengths and 
weaknesses of the literature. Additionally, any omissions or deficiencies may be identified 
which can then assist with clarification and identification of future research pathways. 
 
The review will then discuss recommendations for ongoing research aiming to 
critically assess and evaluate the impact of any potential environmental, geographical, 
cultural and/or social factors that may influence both the incidence and prevalence of 






The aim of the literature search was to capture all relevant, internationally published 
journal research articles between January 2010 and August 2020 that focused on either cross-
sectional (or prevalence) studies and/or cohort (or incidence) studies. Any articles that did not 
specifically relate to preeclampsia incidence and/or prevalence in the country of the research 
origin were excluded. Additionally, any trials that involved animal rather than human 
participation were also excluded. Exact duplicates were removed during each keyword 
process and the sixth and final keyword search was later abandoned following early 
identification of a significant number of search double-ups. Additionally, any articles not 
available in English were also excluded. 
 
The quality and merit of the individual studies included and assessed for the purpose 
of this review will be discussed in further detail in Chapter Three and then further analysed in 
Chapter Four. The author will then evaluate if the review process has identified whether 
previous studies are sufficiently current to continue to inform our understanding of 
preeclampsia rates both globally and within Aotearoa/New Zealand and determine what other 
factors may influence its prevalence and incidence. 
 
For the purpose of this research, the author has chosen to adapt the 2005 Whittemore 
and Knafl design for writing an integrative review (Whittemore & Knafl, 2005), while 
additionally drawing reference and guidance from the updated 2019 Joanna Briggs Institute 






Articles from a wide range of databases and relevant journals meeting with each 
keyword search criteria published between January 2010 and August 2020 were included 
following review of each article’s abstract, introduction, results and discussion sections (see 
p. 48). These were then further scrutinised for relevancy, including consideration for each 
study’s definition and diagnostic criteria for preeclampsia, which was revised for wider 
Australasia in 2014 and again, specifically for New Zealand, in 2018 (Lowe et al., 2015; 
MoH, 2018). These revisions were undertaken to align with the 2014 ISSHP amendments 
that made recommendations to exclude proteinuria as a definitive pre-requisite for 
preeclampsia diagnosis and include fetal growth restriction (ISSHP, 2014, as cited in 
Wojtowicz et al., 2019). All research trials meeting with this study’s criteria and 
identification process were collected and further examined for relevancy for inclusion and 
further examination. During the undertaking of Search Five (and due to acknowledgement 
that the revision of the preeclampsia diagnostic definition in 2014 was yielding potentially 
outdated results), all articles published prior to 2014 were from then on excluded due to a 
lack of relevancy alongside likelihood of inaccurate reporting of the prevalence, incidence 
and rate of preeclampsia globally. 
 
In total, 64 studies from around the globe were analysed from full-text PDF 





3.7 Keyword Searches 
 
Six major and robust key word searches were undertaken within the Wintec ‘OneSearch’ 
library access of key data bases, including: 
 
▪ Academic Search Complete 
▪ CINAHL Complete 
▪ Clinical Trials 
▪ Complementary Index 
▪ Computers and Applied Sciences Complete 
▪ Directory of Open Access Journals (DOAJ) 
▪ Engineering Source 
▪ Gale Academic One File 
▪ Gale Health and Wellness 
▪ PLOS/ONE 
▪ Science Direct 
 
 
An additional search of Google Scholar was also undertaken, when full-text articles could 














*‘OneSearch’ is the name accorded to the Wintec Library’s search tool (powered by EBSCO Discovery Service), which 
provides a single search box for accessing a range of electronic resources, including several research databases as denoted 
above. ‘Complementary Index’, while technically not a subscription database, is an index of full-text resources that are used 




3.7.1 Keyword Search One 
 
‘preeclampsia’ AND ‘geographic location’ 
 
This search resulted in 39 articles of which six were extracted for further scrutiny. 
 
 
3.7.2 Keyword Search Two  
 
‘preeclampsia’ AND ‘geograph*’ 
 
This search yielded 262 results of which 22 were reviewed in closer detail. 
 
 
3.7.3 Keyword Search Three  
 
‘preeclampsia’ AND ‘altitude’ 
 
This search yielded 133 results. Once exact duplicates were discounted, 58 articles 
were then scrutinised, of which four met with inclusion criteria. 
 
3.7.4 Keyword Search Four  
 
‘preeclampsia’ AND (‘international’ or ‘geographic’ or ‘worldwide’) AND 
(‘distribution’ or ‘spread’) 
 
This search yielded 234 results of which fourteen were selected for further scrutiny. 








3.7.5 Keyword Search Five  
 
‘preeclampsia’ AND (‘global’ or ‘international’ or ‘worldwide’) AND (‘occurrence’ or 
‘incidence’) 
 
Keyword search five initially yielded 2154 results. When article publication dates 
were limited to between January 2015 – August 2020 (in order to attempt to exclude any 
study whereby proteinuria was a pre-requisite of diagnostic criteria) results were reduced to 
1649 results. Once any double-ups, non-human trials and articles published in any language 
other than English were excluded, results were further reduced to 993. When this was then 
further limited to academic journal articles, the search was reduced to 830. Articles were then 
perused and any immediately identifiable as adhering to pre-2014 diagnostic criteria for 
preeclampsia were excluded, alongside any in which the true incidence of preeclampsia for 
that specific country could not be clearly determined. The result was then reduced to 132 
articles that met with inclusion criteria for closer investigation, of which 44 were perused in 
close detail.  
 
A sub-search of the Directory of Open Access Journals Search One database was then 
undertaken using the keywords ‘preeclampsia’ AND ‘regional’ AND ‘international’, yielding 
eleven results, of which four met with review criteria. 
 
3.7.6 Keyword Search Six 
 
As previously detailed, a sixth and final keyword search was quickly abandoned 






3.7.7 Figure 1 – Flow Diagram of the Research Article Selection Process 
Flow diagram of the research article selection process for the integrative review - adapted from PRISMA 
 
 
Studies remaining after 
duplicates, articles not in 
English and animal trials 
removed (n=1749) 
Six Keyword Searches undertaken via ‘OneSearch’ multi-database 
search tool identifying 2833 potential articles for review 
Search limited to Jan 2015 – 
Aug 2020 to attempt to 
exclude pre-2014 definition 
of preeclampsia requiring 
proteinuria (n=1649) 
Search limited to academic journals 
only and further duplicates 
excluded (n=819) 
Studies reviewed via abstract, 
introduction, results and 
discussion (n=243) 






64 studies from around the 
globe included in final 
review analysis and 
examined in full-text PDF 
format 
Databases searched via Wintec ‘OneSearch’ Engine: 
▪ Academic Search Complete / CINAHL Complete / Clinical Trials / Complementary 
Index / Computers and Applied Sciences Complete / Engineering Source / Gale 
Academic One File / Gale Health & Wellness / PLOS/ONE / Science Direct /  
▪ Directory of Open Access Journals (DOAJ) 
▪ Google Scholar 
Search Six 




 3.7.8 Table 2 – Characteristics of Included Studies  





















160 women with 
preeclampsia 




































533 teen pregnancies 5.3% no 










Netherlands Linked cohort 
study of 1st & 2nd 
pregnancies 
272,551 women from 
the Dutch Perinatal 













Preeclampsia linked to 
29% of preterm births 
not disclosed not 
disclosed 




187 Andean pregnant 
women living at high 
altitude. Those with PE 
n=20 
10.7% yes 









between January 2011 
– December 2012 
3.1% yes 
da Silva Gama 




720 births involving 
women with 
hypertension from July 
2015 – July 2016 in a 







Dias et al., 
2019. 








Not yet recruited at 
time of writing 
5% 
worldwide 


























151 women diagnosed 
with preeclampsia 









6,367,738 births in 




















preterm birth risk 
factors 








Fox et al., 
2017. 
Ireland Cross-sectional 
study using Irish 
data from the 
SCOPE study 
1774 women, 68 of 
whom developed PE 
3.8% yes 




436 pregnant women 
presenting between 










Audit of 16 NHS 
sites in Wales & 
England 
 1.92% not 
disclosed 
Ivankiv et al., 
2018. 
Ukraine Small scale 
pregnancy 
examination 












161 midwives selected 




Kaduma et al., 
2019. 




131 women diagnosed 
with preeclampsia 










Khader et al., 
2017. 
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India Cohort study 60 women with severe 
preeclampsia between 








from 1996 - 2013 
0.7% yes 
Kongwatanakul 






between January 2012 
– December 2016 
1.9% no 




199 pregnant women 
















Liu et al., 2019 China Population-based 

















Ohio, USA Literature review  3-8% no 











Malik et al., 
2019. 










221 urban (n=136) and 
nomadic (n=85) 
women in Ulaanbaatar 














































of which 1165 
complete pregnancy 
data was available 
7.5% no 







single unit study 
1243 women who 
birthed in the unit 
between January 2019 
and February 2019 
7.6% no 





reviewed; 25 cases of 
preeclampsia and 8 








94 women diagnosed 
on admission with 
preeclampsia 
not disclosed yes 






CCS 88 women hospitalised 
with preeclampsia 
(cases) and 88 healthy 
women (controls), 
n=176 














17738 singleton births; 










200 pregnant women 3% not 
disclosed 



















271, 569 deliveries 
between January 1995 

























































2017 study in 
same facility 
yes 






6585 deliveries; 92 
cases of preeclampsia 
identified 
1.4% yes 





110 health care 
providers interviewed; 
including 75 nurses, 9 
obstetric consultants 
and 26 general 
practitioners 
2 – 16.7% yes 






women, with or 
without preeclampsia 










Unspecified number of 
included review articles 
2 – 16.7% yes 










386 cases screened for 
severe maternal 
morbidity at time of 
delivery admission (Jan 


















6 RCTs from nine 
publications 
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881,700 singleton live 
births between 24-42 
weeks’ gestation, April 
2003 – December 2012 












231,298 deliveries in a 
regional tertiary unit 





Germany Economic impact 
study 
 2% No 









included for analysis 
2.3% general 
rate of PE; 
0.2% rate of 
EOP 
No 






208 women diagnosed 
with preeclampsia 
6.3% Yes 














et al., 2019. 















 4% No 
Vahiddastjerdy 





between March 2009 – 
March 2012 









Study (ROS)  
(hospital-based) 
172 women diagnosed 




Wagnew et al., 
2016 
Ethiopia Five-year RCS 
(hospital-based) 
1809 women with 
preeclampsia/eclampsia 
from 43 hospitals in 
Addis Ababa 











14,568 women from 





Poland Single tertiary 
unit retrospective 
cohort study 
214 women diagnosed 
with preeclampsia 

























yes / no 
Xiao et al., 
2014. 
China Retrospective 















January 2011 – 
December 2011 




of PE not 
reported 
yes 






pregnancies ≥20 weeks 
with live or stillborn 











Yu et al., 2020. Taiwan Nationwide 
study 
1,347,672 live births 






3.8 Search Results – Synthesis of Findings from Table 2 
 
In total, four studies from the USA were analysed, two from Canada, five from Brazil, 
two from Bolivia, one each from French Guiana and Haiti, one each from Israel, Jordan and 
Saudi Arabia, two from Iran, one each from Hungary, Ireland, Norway, Poland, Germany, the 
Netherlands and Spain, two each from the United Kingdom and the Ukraine, one each from 
Australia, Hawaii and French Polynesia, four from China, five from India, one each from 
Mongolia, South Korea, Japan and Thailand, two each from Taiwan and Indonesia, one each 
from Morocco, the Democratic Republic of Congo, Rwanda, Zambia, and Zimbabwe, two 
from South Africa and three each from Ethiopia and Nigeria. There were no studies 
emanating from New Zealand that met with this thesis’ inclusion criteria, meaning scope for 
future research is warranted.   
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Additionally, many of the studies included beyond 2014 (when ISSHP revision of 
diagnostic criteria for preeclampsia came into effect) either required proteinuria for inclusion 
and/or did not report on their country’s overall rate or incidence. Furthermore, many studies 
that retrospectively examined reporting of preeclampsia incidence in line with the 2014 
revisions, noted and/or were suggestive of, higher rates of the disorder, once new criteria 
were applied. 
Outcomes and reporting on the incidence and prevalence of preeclampsia in each of 




Chapter Three has evaluated the research method drawn upon to guide this thesis and 
its critique of the global and national incidence and prevalence of preeclampsia. The method 
of an integrative review design method has been described and explored to provide evidence 
of validity. Additionally, the process undertaken to effectively search, review and synthesise 
studies meeting with the inclusion criteria has been described for reader clarification. 
 
Merits of the quantitative evidence pyramid (referencing the structure of an 
integrative review) have been described and defined. Review objectives have been evaluated, 
and the method of the integrative review explored in depth to provide rationale for merit of 
selection. Inclusion criteria of selected studies and the applied search strategy have been 
clearly defined by way of explanation of each keyword search undertaken. Inclusion of visual 
explanations via implementation of a search flow diagram and integration of a table of 
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characteristics of included studies were also incorporated to both support and enhance further 
understanding of the integrative review process. 
 
Chapter Four will now explore and further evaluate both the global as well as national 
incidence and prevalence of preeclampsia in Aotearoa/New Zealand and provide comment 
upon emergent themes of interest that may impact upon future practice and research 
opportunities. Additionally, it will briefly highlight any noted limitations of the research that 








“Where disease occurs is a matter of great importance ... (as) ... comparison of 
disease rates in different places may strongly suggest aetiological factors or serve as 
a stimulus to further fruitful investigation …”                                                        





Chapter Four will explore and further evaluate the global and national incidence and 
prevalence of preeclampsia in Aotearoa/New Zealand and comment upon emergent themes of 
interest that may impact upon future practice and research opportunities. Additionally, any 
noted limitations of this research review project will be highlighted as areas of interest for 
future research study and inquiry. 
 
4.2 Global Incidence & Prevalence of Preeclampsia      
2010 - 2020       
 
4.2.1 Table 3 – Estimates of the Global Impact of Preeclampsia 2010 - 2020 
Estimated global incidence & prevalence of preeclampsia 2 – 7% 
Estimated rates of global maternal & perinatal morbidity due to preeclampsia 15 – 20% 
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Global incidence of preeclampsia may range anywhere from 2 – 17% (Poropet et al., 
2018), and is responsible for 15 – 20% of severe maternal and perinatal morbidity and 
mortality cases, including 60,000 maternal deaths and more than 500,000 premature births 
each year (Ma’ayeh & Costantine, 2020), particularly in low-middle income countries (Elliot 
et al., 2014; Deng et al., 2019). Incidence is estimated to be seven-times higher in developing 
nations such as India (Malik et al., 2019), while prevalence in certain Latin American 
countries is estimated to be greater than 25%, giving rise that differing rates globally may be 
attributed to unique geographic, social, economic and racial differences (Ma’ayeh & 
Costantine, 2020).  
A 2011 Canadian study examining the epidemiology of preeclampsia and other 
hypertensive disorders of pregnancy reported a 3% incidence in the USA, 3.3% in New 
Zealand (based on a 1995 prospective study; Stone et al., 1995) 3% in Sweden, 4.5% in 
Denmark and 3% in Norway. Incidence rates were higher in some North American regions, 
including 8.4% in Washington State and 8.7% in Nova Scotia (which correctly defined 
preeclampsia without required inclusion of proteinuria) (Hutcheon et al., 2011). Authors 
additionally noted a seasonal variation of incidence of preeclampsia; in Northern regions of 
the globe, incidence is more common amongst winter births, with Finnish women reporting a 
two-fold higher risk for preeclampsia than women in Southern Europe. Additionally, in 
Zimbabwe, there is marked variance in incidence between the dry and wet seasons (Hutcheon 
et al., 2011).  
Overall, global rates have risen since the last systematic review and meta-





4.2.2 Emergent Themes of Interest: 
 
▪ Geographic, social, economic and racial differences may account for differing 
global rates of preeclampsia. 
▪ Environmental impacts alongside a noted seasonal variation of preeclampsia 
rates warrant further exploration. 
▪ Low to middle-income nations (including New Zealand) report higher rates of 
preeclampsia compared with wealthier countries. 
▪ Global prevalence and incidence of preeclampsia has risen since the last large-





4.2.3 North America 
 
United States of America 
 
In the USA, preeclampsia affects approximately 4% of pregnancies and is the second 
leading cause of maternal mortality and serious perinatal morbidity, including eclamptic 
seizure, multi-organ dysfunction, fetal growth restriction, low birth weight and perinatal 
demise (US Preventative Services Task Force, 2017). This rate (or reported rate) has 
increased slightly from an earlier study emanating from Washington State in 2014, where the 
preeclampsia rate was noted to have increased from 2.9 to 3.1 per 100 singleton births 
between 2000 and 2008, with rates of early and late-onset manifestation reported as 0.3% and 
2.7% respectively (Lisonkova et al., 2014). However, inclusion of proteinuria as a 
requirement for diagnosis may account for under-reporting prior to acceptance of the new 
diagnostic criteria in 2014 (ISSHP). This rate of 3% was also reported in a 2019 US study, 
which similarly drew upon the 2013 American College of Obstetricians and Gynecologists 
(ACOG) definition of preeclampsia requiring proteinuria as a definitive diagnostic feature, 
meaning that a 4% estimate may indeed be more accurate when drawing upon the updated 
2014 ISSHP guidelines (Calimag-Loyola & Lerma, 2019). 
Additionally, preeclampsia is noted second only to previous preterm birth as a leading 
independent risk factor for preterm birth, a morbidity factor which incurs a burden of more 
than USD$26 billion per annum upon the US health service (Ferrero et al., 2016). Similarly, 
another 2016 study undertaken in California at the Cedars-Sinai Medical Centre reported 
preeclampsia and eclampsia as the second most common cause of severe maternal morbidity 
(10.7%) after haemorrhage (71.3%) (Ozimek et al., 2016). Given that preeclampsia and 
eclampsia may lead to and/or exacerbate haemorrhage and disseminating intravascular 
coagulation (DIC), and considering that this study did not provide a clear definition of the 
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diagnostic criteria for preeclampsia, incidence and prevalence of the disorder may possibly be 




In Canada, preeclampsia incidence has increased from 2.64% of deliveries in 1989 to 
5.06% in 2012 (Auger et al., 2015, as cited in Sacks et al., 2018). A 2016 retrospective 
population-based cohort study from April 2013 to December 2012 additionally ascertained 
that risk for preeclampsia alongside preterm birth between 24 and 36 weeks’ gestation 
differed significantly according to maternal origin; specifically, Canadian-born women were 
far less likely to experience this outcome (4.0 per 1000) compared to residing Canadian 
immigrant women, especially those hailing from Nigeria, the Philippines, Colombia, Jamaica 
and Ghana (6.6 per 1000 to 8.3 per 1000 rate in sequential order), confirming ethnicity and 
socio-economic factors as pre-disposing risks for preeclampsia (Ray et al., 2016). 
 




In Bolivia, the maternal mortality rate has, for many years, been consistently reported 
at more than twice the rate of all other Latin American countries and is currently decreasing 
by only 3.5% per annum, half the recommended reduction target. Preeclampsia is currently 
Bolivia’s second highest cause for maternal death (and likely also associated with the first 
cause, postpartum haemorrhage) and afflicts as many as 20% of all pregnancies. For those 
mothers and babies who do survive, the risk for developing long-term cardiovascular and 
other associated co-inflammatory conditions (including chronic hypertension and diabetes 
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mellitus) is high. While limited health care resources and socio-economic deprivation are 
contributing factors, two-thirds of Bolivians live in high-altitude (often remote rural) areas, a 
factor linked to poor fetal growth and pregnancy-associated hypertensive disorders, including 
preeclampsia (Toledo-Jaldin et al., 2019). Given that early-onset preeclampsia is particularly 
dangerous (and more likely to be severe) amongst indigenous Andean populations living at 
high altitude, investigating other influences such as serum levels of pro-inflammatory 
cytokines may help to determine genetic risk factors and enable timely and early preventative 
medical interventions, including low-dose aspirin and oral calcium supplementation (Davila 
et al., 2012). Additionally, with statistics confirming that Andean (and Tibetan) women have 
a two to four-fold increased incidence of preeclampsia yet lower risk for small-for-
gestational-age (SGA) babies than their low-altitude neighbours, further investigation into 
genetic adaptations to altitude (which could support the theory that the aetiologies of 
preeclampsia and SGA differ) are warranted (Browne et al., 2011). 
 
Brazil 
In Brazil, preeclampsia accounts for 18% of all preterm births and is a major 
contributing factor towards both short and long-term neonatal morbidity rates, including the 
consequences of iatrogenic prematurity and growth restriction. Additionally, hypertensive 
disorders (including preeclampsia) are recognised as the leading cause of death in Brazil and 
are collectively responsible for 23% of all maternal deaths (Bakwa-Kanyinga et al., 2017; 
Dias et al., 2019). Of 27 referral hospitals assessed in a 2019 nationwide cross-sectional 
surveillance PREPARE stepped wedge trial, 10 were recognised as providing inadequate 
care, exacerbating risk for severe maternal morbidity (Dias et al., 2019). Incidence of 
hypertensive disorders of pregnancy in Brazil ranges from 14.4 – 18.4%, with an overall 
preeclampsia rate of approximately 7.5 – 8.9% (Bergamo et al., 2015 as cited in Kharaghani 
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et al., 2016; Mayrink et al., 2019; da Silva Gama et al., 2020). Associated risk factors for 
preeclampsia in the Brazilian population include diabetes mellitus and obesity, giving rise to 
serious maternal adverse outcomes such as postpartum haemorrhage, chronic hypertension, 
placental abruption, renal and hepatic failure and death (Bakwa-Kanyinga et al., 2017). 
Researchers involved with the aforementioned 2019 PREPARE trial also assert there may be 
additional pathophysiological influences and risk factors relevant to Brazil (and perhaps also 
with other low to low-middle income countries) that may account for this high prevalence, 
including poorly funded health services that may lead to iatrogenic early delivery (possibly 
both hastily and unnecessarily), via (predominantly) caesarean section (Dias et al., 2019). 
 
The Preterm SAMBA (Screening & Metabolomics in Brazil and Auckland) trial (also 
published in 2019) was conducted in five different health centres throughout Brazil and 
involved 1165 eligible (healthy and primiparous) participants (Mayrink et al., 2019). This 
study also reported an overall incidence of preeclampsia of 7.5%, with 16.1% developing 
early-onset preeclampsia (prior to 34 weeks’ gestation), while the remainder developed it at 
or after 34 weeks’ gestation (Poon et al., 2010; Mayrink et al., 2019). Poor maternal and 
neonatal outcomes for those afflicted with preeclampsia were noted, including increased risk 
for caesarean section, prolonged hospital admission, preterm delivery at less than 34 weeks’ 
gestation, low birth weight, Apgar scores of less than 7 at 5 minutes of age and increased risk 
for fetal demise.  Data analysis was able to identify three factors that attributed to significant 
risk for development of preeclampsia, namely increased or rapid maternal weight gain in 
pregnancy, pre-existing maternal obesity, and a diastolic blood pressure at 20 weeks’ 




In French Guiana, reported rates of preeclampsia range from 2 – 8%. However, a 
2020 study involving 1243 women birthing in a tertiary unit in the capital Cayenne reported a 
12.6% rate of pregnancy-related hypertensive disorders, of which preeclampsia accounted for 
61.4% of cases with an overall incidence of nearly 8%; due likely to the tertiary status of the 
hospital, to where women diagnosed with hypertension in pregnancy would be referred. 
Additionally, there is a higher rate of chronic hypertension amongst the French Guiana 
population (23.5%) when compared with other South American nations. 52.4% of women 
included in the study were South American, 45.1% were from the Caribbean and one woman 
was of African origin; all of whom have been identified as at particular risk for preeclampsia. 
Co-morbidities were determined as gestational and pre-existing diabetes mellitus and low-
socio-economic status. Proteinuria was not a requirement for diagnosis (as per 2014 updated 
criteria) but was noted as significant (≥0.3g/L protein:creatinine ratio) in nearly 60% of cases 





The only recent data available reporting incidence of preeclampsia in Argentina was 
cited in a 2016 Moroccan study at 3.2% (Marchand et al., 2016). Data from other Central and 
South American countries was not extrapolated from the keyword search or may have not 





4.2.5 The Caribbean 
 
Haiti 
In Haiti, the incidence of preeclampsia is reported to be as high as 18% (Raghuraman 
et al., 2014, as cited in Gagliano et al., 2016). Furthermore, the prevalence of hypertension-
induced preeclampsia contributes to nearly 40% of all maternal deaths (WHO, 2016, as cited 
in Gagliano et al., 2016). In a small rural birthing cohort in Haiti (436 women), 13.1% met 
with criteria for diagnosis of pre-partum hypertension (systolic pressure of greater than 
140mmHg and/or diastolic pressure of greater than 90mmHg on at least two occasions at 
least four hours apart), with an astounding 65.5% of women being diagnosed with postpartum 
hypertension only, suggesting that preeclampsia may have been missed antenatally due to the 
inclusion of proteinuria as an antepartum diagnostic requirement. Rates of preeclampsia in 
Haiti may in fact be far higher than has been reported, likely due to various considerations, 
including poor access to advanced health care services, extreme poverty, as well as political 





4.2.6 Western & Central Eastern Europe 
 
The European continent is reported to have an overall approximated incidence 




In Germany, preeclampsia complicates approximately 2% of pregnancies while 
hypertensive disorders of pregnancy are the most common cause for maternal mortality in 
Europe, giving researchers impetus to examine the economic feasibility for use of predictive 
serum blood tests for preeclampsia, specifically the soluble fms-like tyrosine kinase 1: 
placental growth factor ratio (sFlt-1:PlGF) (Schlembach, et al., 2018). Results indicate that 
use of this test is likely to reduce unnecessary hospitalisation for low-risk women while 
ensuring those identified at high-risk will receive appropriate care and management, resulting 
in significant health dollar savings (Schlembach et al., 2018). 
 
Hungary 
A study undertaken in Hungary in 2015 examined the impact of hypertensive 
disorders of pregnancy comparing results based on the 2013 ACOG criteria for preeclampsia 
diagnosis (requiring proteinuria) and the ISSHP 2014 criteria (Rigo et al., 2015). 775 women 
admitted to the Semmelweis University obstetrics and gynaecology department diagnosed 
with hypertensive disorders and singleton pregnancies between January 2012 and December 
2014 were enrolled. Results found that the redefining of preeclampsia diagnosis according to 
the ACOG 2013 criteria increased the rate of preeclampsia by 8.2% and by a staggering 
17.2% when the ISSHP 2014 criteria were applied (when compared with earlier 2002 ACOG 
classification). Additionally, while the incidence of preeclampsia was indeed increased when 
69 
 
applying the new diagnostic criteria, perinatal outcomes were not significantly influenced 
(Rigo et al., 2015). 
 
Iceland 
A 2018 Icelandic study concluded that hypertensive disorders of pregnancy 
complicate up to 10% of pregnancies in that country, with preeclampsia affecting 
approximately 3.2% of these. Of 63,014 children analysed between the ages of nine and 
fifteen years, 2026 had been exposed to preeclampsia in-utero. Not only were those children 
more likely to have been born SGA and prematurely with lower Apgar scores, but incidence 




In Ireland, preeclampsia affects 2 – 3 % of all pregnancies and 5 – 7% of nulliparous 
pregnancies and has significant impact on the economic health costs (Fox et al., 2017). Given 
that this study required proteinuria onset as a diagnostic pre-requisite for preeclampsia, 




A 2019 Dutch study determined the rate of preeclampsia to account for approximately 
3% of all pregnancies in Holland, with prevalence at 2.5% for first pregnancies and 0.9% for 
second pregnancies, following a linked cohort of 272,551 women whose data had been 
collated by the Dutch Perinatal Registry between 2000 and 2007 (Bernardes et al., 2019). 
However, given that the criteria for confirmation of preeclampsia required proteinuria 
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alongside hypertension during the period of data collection, under-reporting can be suspected, 
given the current, revised diagnostic criteria. 
 
Norway 
In 2015, the rate of preeclampsia in Norway was reported as 3.8% for the nulliparous 
population, with a 4.3% overall occurrence (Austdal et al., 2015). The study however only 
included a small cohort of 599 women, all with moderate to high risk for developing 
preeclampsia (including nulliparity, previous hypertension or risk based on first trimester 
urine and serum metabolomic results). Furthermore, researchers determined proteinuria as a 
diagnostic inclusion requirement (Austdal et al., 2015). 
Another (2017) Norwegian study examining seasonal and other preventable 
environmental contributors to preeclampsia (including smoking) determined that 
preeclampsia risk was indeed related to season, with higher risk associated with spring 
conceptions and lower risk associated with autumn conceptions (Weinburg et al., 2017).  
Yet another (2018) Norwegian population-based cohort study of 630255 pregnancies 
between 1999 and 2009 found that the rate of preeclampsia was 5.6% amongst primiparous 
women and 2.6% for multiparous women. Furthermore, the risk of eclampsia and HELLP 
syndrome was 3.5% for those women diagnosed with preeclampsia, meaning the impact on 
the Norwegian health service structure was significant (Engjom et al., 2018). A limitation of 
this study, however, was the requirement for proteinuria as part of the diagnostic criteria, 







A comprehensive cohort study of 214 women between 2013 – 2017 examined 
laboratory and clinical findings according to the 2014 ISSHP criteria in Krakow University 
Hospital in Poland (Wojtowicz et al., 2019). The study found that the overall incidence of 
preeclampsia according to the new diagnostic criteria was 1.7%, while those diagnosed with 
early-onset preeclampsia (<34 weeks’ gestation) had higher risk for severe perinatal and 
maternal adverse pregnancy outcomes, including cardiorespiratory and haematological 
complications (Wojtowicz et al., 2019). Limitations of the study were the comparatively 
small cohort and further, larger-scale studies on a nationwide scale are warranted. 
 
Turkey 
A 2011 Turkish study of women admitted with preeclampsia, eclampsia and/or 
HELPP syndrome between 1998 and 2002 to the Atatürk University, Obstetrics and 
Gynaecology Department in Ankara sought to determine a distribution map of the effects of 
altitude upon the rate of HELLP syndrome and eclampsia. Authors concluded that rates of 
HELLP and eclampsia were raised at high altitude when compared with their low-dwelling 
counterparts, and that early diagnosis was vital in order to prevent significant maternal 
morbidity and mortality risk (Kumtepel et al., 2011). 
 
Spain 
In Spain, a prospective cohort study of 7908 pregnancies (of which 6893 were 
included in the final data analysis) in two Barcelona hospitals between March 2014 and 
September 2017 reported an incidence of 2.3% of preeclampsia, with incidence of early-onset 
preeclampsia (< 34 weeks’ gestation) reported at 0.2% (Serra, et al., 2020). The study sought 
to assess the multivariate Gaussian distribution model as a reliable screening tool for early-
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onset preeclampsia (including maternal risk factors, early placental growth factor 
determination at 8 weeks’ gestation and other biophysical variables) and found it a feasible 
predictor between 11 to 13 weeks’ and 6 days’ gestation. Authors concluded that the model 
should now be compared with other predictor tools (using regression analysis) and that a 
nationwide trial could also be considered (Serra et al., 2020). 
 
Ukraine 
A 2017 case-control study of 300 singleton pregnant women (aged 16 – 43 years; 100 
diagnosed with EOP, 100 with LOP and 100 as a control) who delivered either a live or still 
birth in the obstetric department at the L’viv Regional Clinical Hospital in the Ukraine 
between June 2014 to June 2017 sought to evaluate differences in risk factors and birthing 
outcomes when comparing early versus late-onset preeclampsia (Markin & Medvyedyeva, 
2017). Although the study relied on the former ‘gold standard’ definition of preeclampsia 
(that is, to include proteinuria in diagnostic criteria), maternal age > 35 years, smoking during 
pregnancy, pre-existing obesity and hypertension were associated with significant risk for 
both early and late-onset disease manifestation, while chronic hypertension and fetal 
congenital anomalies were more strongly associated with early-onset preeclampsia. Diabetes, 
nulliparity, and teenage pregnancy were additionally cited as strongly identified risk factors 
for late-onset preeclampsia. Overall, early-onset preeclampsia was associated with increased 
risk for IUGR, prematurity (largely due to iatrogenic pre-term delivery) and severe neonatal 
morbidity and mortality, while late-onset preeclampsia rarely led to fetal or neonatal demise 
(Markin & Medvyedyeva). However, overall incidence of preeclampsia in the Ukraine was 




A later (2018) Ukrainian study examining vaginal and mammary gland skin 
microbiota in 25 women with preeclampsia and 25 ‘healthy’ women experiencing a normal 
physiological pregnancy, cited the incidence of preeclampsia in the Ukraine to range from 6 – 
16% but did not offer any comment on why this range variation was so wide. Furthermore, 
classification of preeclampsia was according to a 1995 amendment to the Order of the 
Ministry of Health of Ukraine (2004), in which proteinuria was part of the mandatory 
diagnostic criteria, meaning many cases were potentially missed (Ivankiv et al., 2018). 
 
United Kingdom 
An audit undertaken in sixteen National Health Service (NHS) sites across both 
England and Wales between 2016 and 2017 found the incidence of preeclampsia to range 
from 3.25% to 0.3%, with an overall mean of 1.92%, lower than previously reported, which 
was unexpected, although diagnostic inclusion criteria was not described (Hendy et al., 
2017). Authors commented however, that accurate and recent data reporting on the incidence 
of preeclampsia in high-income countries is currently extremely limited and their own 
findings were potentially flawed due to coding inaccuracies and/or missed diagnosis, 
concluding that there is an opportunity for future important research opportunities (Hendy et 
al.). 
Leading from this, a 2020 retrospective study of 66,964 singleton pregnancies 
between January 2011 and June 2018 who delivered at King’s College Hospital in London 
(of whom 2.8% were previously identified as having preeclampsia based on former ACOG 
and ISSHP criteria) were reviewed according to ‘new’ ACOG 2013 and ISSHP 2014 criteria 
(the latter of which no longer requires proteinuria as a diagnostic prerequisite) (Khan et al., 
2020). Following this review, incidence of preeclampsia climbed to 3% using ‘new’ ACOG 
criteria and 3.4% when ‘new’ ISSHP 2014 criteria were applied, meaning overall incidence at 
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the time of data collection was significantly under-reported. Authors concluded that the new 
definition of preeclampsia resulted in an increase of diagnosis but added that the additional 
identified cases manifested milder pathogenic symptoms, inferring that early diagnosis could 
both critically and positively impact on pregnancy and perinatal outcomes, alongside 
maternal morbidity and mortality risk (Khan et al., 2020). 
 
4.2.7 The Middle East 
 
Iran 
In Iran, preeclampsia may account for as much as 7.7% of the total mortality rate 
(Vahiddastjerdy et al., 2016), with the prevalence of hypertensive disorders in pregnancy 
reported at 8.1% (Asgharnia et al., 2017). Following a 2016 systematic review and meta-
analysis (in which 36 separate international and Iranian studies were assessed) an increasing 
prevalence in preeclampsia (from 0.3% between 1996 – 2005, to 0.7% between 2010 – 2013) 
was noted alongside a marginal decline in eclampsia (Kharaghani et al., 2016). However, 
authors reported a wide discrepancy in the results following meta-analysis, meaning a precise 
rate of incidence could not be determined. Furthermore, the systematic review definition 
criteria for study inclusion adhered to the former (now defunct) diagnostic definition of 
preeclampsia (requiring proteinuria alongside hypertension after 20 weeks of pregnancy), 









A 2018 Israeli population cohort study examining 231,298 deliveries between 1991 
and 2014 in a regional tertiary medical centre determined a 4.1% rate of preeclampsia, 
although no diagnostic definition of preeclampsia was described. The study sought to 
examine congenital cardiovascular predispositions and cardiovascular risk factors in children 
exposed in-utero to preeclampsia and found a significant association between the two (Sacks 
et al., 2018). However, given the cohort included in the study drew upon former diagnostic 
criteria requiring proteinuria, under-estimation of rates of preeclampsia may be suspected. 
In 2020, an Israeli retrospective cohort study sought to explore the environmental 
effects of climate change secondary to global warming alongside emergent evidence 
suggesting the impact of environmental factors upon the pathophysiology of preeclampsia. 
Additionally, and as supported by other international studies previously cited, the impact of 
socio-economic status alongside environmental factors including rural lifestyle and 
seasonality effects was also considered (Shashar et al., 2020). Of 64,566 deliveries (from 
31,101 women) that met with inclusion criteria in the Negev region of Southern Israel, 7% of 
women and 4.1% of deliveries were affected by preeclampsia, with their babies more likely 
to have lower Apgar scores and lower birth weights. Women diagnosed with preeclampsia 
were likely to be older, and of Jewish ethnicity, with diagnosis occurring mostly in late pre-
term gestations between 34 and 36+6 weeks resulting in pre-term delivery. However, 
seasonal variance was also confirmed to increase likelihood for preeclampsia when the 
majority of the pregnancy occurred during the summer months – in this instance, women 
were more likely to be rural and poorer; namely nomadic women of Bedouin-Arab ethnicity 
when compared with their urban, wealthier and mostly Jewish counterparts, for whom air-
conditioning and air-filtration systems are more common, particularly during warmer periods. 
Authors concluded therefore that environmental (alongside socio-economic) factors may 
76 
 
indeed affect maternal heat homeostasis, causing reallocation of maternal resources away 
from the developing fetus, thereby increasing risk for preeclampsia. This, when placed 
alongside global warming and increased socio-economic deprivation, validates further 
exploration of these risks alongside the potential for a rise in preeclampsia incidence (Shashar 
et al., 2020). 
 
Jordan 
In 2017, a national study of perinatal mortality was undertaken in Jordan, with one 
objective focused on estimating the incidence of preeclampsia, its associated risk factors, and 
impact on neonatal morbidity and mortality rates (Khader et al., 2018). Diagnostic criteria 
again included proteinuria, meaning that the reported 1.3% overall incidence rate amongst the 
21,928 women included in the study is likely unreliable. Authors did note a higher rate of low 
birth weight, risk for prematurity and neonatal encephalopathy and neonatal mortality rate in 
those babies born to women with preeclampsia, although further exploration with more recent 
diagnostic criteria for preeclampsia is warranted. 
 
Saudi Arabia 
A multi-centre cohort study undertaken in three Riyadh hospitals in Saudi Arabia 
between November 2013 and March 2015 determined a 1.1% incidence of preeclampsia 
amongst the 14,568 women participants (Wahabi et al., 2016). However, given that 
diagnostic criteria for preeclampsia required the inclusion of proteinuria alongside new onset 
of hypertension at ≥ 20 weeks’ gestation, under-reporting is highly likely. Saudi Arabia is a 
high-income country with a well-serviced health care system, and is predominantly mono-
cultural (70% Saudi population) with a rapid rise in urbanisation and Westernisation, 
resulting in rates of obesity and gestational diabetes that rank amongst the world’s highest 
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(Wahabi et al., 2016). As both these co-morbidities increase risk for preeclampsia, likelihood 
of a further increase in preeclampsia rates may be anticipated in the absence of preventative 
health measures and initiatives. 
 
4.2.8 The African Continent 
 
The African continent is reported as having the highest international incidence of 
preeclampsia, estimated to afflict 4 – 10% of all pregnancies, with sub-Saharan rates reported 
to be as high as 44% (Benfateh et al., 2018; Nwanodi, 2016; Vata et al., 2015). 
 
Morocco 
A small review of 401 preeclamptic cases reported in a Casablanca Hospital between 
2010 – 2011 found an incidence of 7.1%, with key risk factors for preeclampsia identified as 
primiparity, limited antenatal care, obesity and chronic hypertension (Benfateh et al., 2018). 
Diagnostic criteria for preeclampsia included hypertension (blood pressure ≥ 140/90mmHg) 
alongside significant proteinuria (≥0.3g/24 hour collect or ≥2+ protein on urinary dipstick 
screening), meaning accuracy of reporting may be unreliable. 
 
Democratic Republic of Congo 
Kinshasa, capital city of the Democratic Republic of Congo (and second-most densely 
populated area within the sub-Saharan region) reports an overall high annual incidence of 
preeclampsia (approximately 9%) but with significant rate variation noted between the wet 
and dry seasons, respectively 6% versus 13% (Moyene et al., 2016). Alongside a lack of 
readily-available fresh fruit and vegetables (a known risk factor for preeclampsia) during the 
dry season, authors of a 2016 Kinshasa seasonal case-control study (of healthy women and 
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those diagnosed with preeclampsia in the rainy season between March and April 2011 and the 
dry season from July to September 2011) additionally acknowledged the correlation between 
pro-oxidant metals (including lead) and associated risk for preeclampsia (Moyene et al., 
2016). Serum lead levels have been determined to increase during dryer months due to 
greater likelihood of lead-contaminated soil dust inhalation (Laidlaw et al., 2005; Moyene et 
al.). Once again, diagnostic criteria for preeclampsia required the presence of proteinuria, 
meaning both coding discrepancy and inaccuracy of reporting could be possible. 
 
Ethiopia 
In Ethiopia, prevalence of preeclampsia may account for 8.4% of all adverse 
pregnancy outcomes, ranking as third amongst the top four causes of maternal mortality and 
contributing significantly to risk for maternal death (Endeshaw et al., 2016). A facility-based 
case-control study undertaken in Bahir Dar City in north-western Ethiopia sought to evaluate 
the risk of obesity and dietary habits on incidence of preeclampsia but was limited by its 
small scale, interviews reliant on self-reporting, and diagnostic inclusion criteria defining the 
disorder as “hypertension accompanied by proteinuria, with or without generalised oedema” 
(p. 2), making it therefore difficult to predict reliability of the study’s figures (Endeshaw et 
al.).  
An earlier (2015) assessment of prevalence of preeclampsia in the Dilla region of 
Ethiopia between January 2009 and December 2012 found the incidence rate to be 2.23% yet 
reiterated that confirmation of proteinuria alongside hypertension was a requisite part of the 
diagnostic inclusion criteria. Additionally, authors acknowledged that no in-depth studies on 
preeclampsia in Ethiopia have thus far been undertaken, calling for urgent government 




In 2016, a retrospective cross-sectional study reviewing five years of medical records 
in selected government hospitals throughout the capital city Addis Ababa as well as other 
Ethiopian regions, determined that rates of preeclampsia had increased from 2.2% in 2009 to 
5.58% in 2013. For preeclampsia to be determined, authors defined the disorder as “new 
onset of hypertension and proteinuria after 20 weeks’ gestation in a previously normotensive 
woman” (p.2), meaning reliable reporting of actual rates and incidence may be queried 
(Wagnew et al., 2016). 
 
Rwanda 
A 2020 combined retrospective and prospective study undertaken in two teaching 
hospitals in Kigali, Rwanda sought to determine prevalence of preeclampsia and eclampsia 
and whether there were seasonal variations (Mutabazi et al., 2020). Over a two-year period 
(December 2015 – August 2017) involving close to 20,000 births, a 2.0% rate of 
preeclampsia was reported. Risk factors identified were obesity, a history of hypertension, 
pre-existing and gestational diabetes. While two-thirds of women diagnosed with 
preeclampsia presented during the rainy season, timing of conception was not noted as 
significant (Mutabazi et al.). However, despite international revision of preeclampsia 
diagnosis criteria in 2014 (ISSHP, 2014; SOMANZ, 2014) this study maintained a 
requirement for proteinuria alongside hypertension for case inclusion, meaning under-










Nigeria reports a rate of preeclampsia ranging from 2 – 16.7% (Osungbade & Ige, 
2011), with more than 30,000 women dying each year from the disorder. There is marked 
regional variation, with preeclampsia accounting for 40% of all maternal mortality cases in 
North Nigeria, while prevalence in the south ranges from 5.6 – 7.6% (Olaoye et al., 2019). 
Low socio-economic status, poverty, poor diet, poor access to health and maternity care, 
previous history of hypertensive disorders and a generalised lack of knowledge about the 
disorder amongst health care providers, are noted as key risk factors (Olaoye et al.). 
A 2018 retrospective study of 89 obstetric patients admitted to a Southeast Nigerian 
hospital between the 1st of January 2012 and December 2013 reported a 6.7% rate of severe 
preeclampsia, a 22.5% rate of eclampsia, and a further 36% rate of uterine rupture. Lack of 
antenatal care, inadequate health care services and low socio-economic status were 
significantly associated with increased maternal mortality risk. However, given the study 
drew upon proteinuria as a diagnostic requirement for preeclampsia, likelihood of under-
reporting of preeclampsia (until manifestation of severe preeclampsia was identified) may be 
suspected (Ozumba et al., 2018).  
Another (2019) retrospective case-control study undertaken in the Alex Ekwueme 
Federal University Teaching Hospital in Abakaliki, Nigeria between January 2012 and 
December 2015 determined a preeclampsia prevalence of 1.4% amongst 6585 deliveries (Obi 
et al., 2019). Again, proteinuria was required alongside gestational hypertension as part of the 






In Zimba Mission Hospital, Zambia, a 2018 study of all 1712 deliveries in 2017 found 
and reported an overall rate of 2.5% for all pregnancy hypertension disorders and 1.5% rate 
of preeclampsia and drew on the current and revised diagnostic criteria for hypertension 
alongside proteinuria and/or evidence of other organ failure (Miyoshi et al., 2018). Given the 
rate of eclampsia was determined at 19%, failure to diagnose and treat preeclampsia in a 
timely manner with interventions such as magnesium sulphate (administered intramuscularly 
in this setting for low-income women as part of hospital protocol) was identified by authors 




Limited reporting has thus far emanated from Tanzania, with data from one medical 
centre reporting a preeclampsia rate of 1.6% (Kaduma et al., 2019). Given the small size of 
the study (393 women) and diagnostic inclusion criteria requiring proteinuria, many cases 
may not have been adequately captured. An earlier 2018 retrospective population study of 
17,738 singleton deliveries (drawn from data from the Kilimanjaro Christian Medical Centre 
Birth Registry between July 2000 and May 2013) reported a preeclampsia rate of 3.3%, and 
noted the association between maternal obesity and risk for preeclampsia, but again relied 






Overall incidence of severe preeclampsia and eclampsia in Mpilo Central Hospital in 
Bulawayo, Zimbabwe was determined to be 1.3% in 2017 (Ngwenya, 2017, as cited in 
Ngwenya et al., 2019), although diagnostic inclusion criteria for preeclampsia required 
manifestation of significant proteinuria alongside hypertension after 20 weeks’ gestation. 
Other studies reporting specific rates and/or national incidence of preeclampsia in Zimbabwe 
have not yet been determined and/or were not available at the time of writing this thesis. 
 
South Africa 
Between 2011 and 2013, hypertensive disorders accounted for 14.8% of all maternal 
deaths in South Africa (Pretorius et al., 2018). Depending on ethnicity, overall incidence of 
preeclampsia is estimated to range from 3 – 7% in healthy primigravid women and between 1 
– 3% in multigravida pregnancies (Aung et al., 2018). However, prevalence of preeclampsia 
amongst South African Black primigravid women is reported to be as high as 12% and 
accounts for 10-15% of all maternal deaths, highlighting the severe impact of the disorder on 
indigenous women when compared with other ethnic populations (Aung et al.). 
____________________________________________________ 
 
There were no other studies undertaken in African nations that met with search 
criteria, although figures related to incidence in Uganda and Angola (3.7% and 0.9% 
respectively) were cited (but not explored) in a 2016 cross-sectional study undertaken in 




4.2.9 Central & South East Asia 
 
Mongolia 
A 2016 cross-sectional study of 236 urban and 85 rural (including nomadic) women 
conducted in two maternity hospitals in the Mongolian capital of Ulaanbaatar found an 
overall incidence rate of preeclampsia of 4.1%, when diagnostic criteria for new-onset of 
hypertension after 20 weeks’ gestation alongside proteinuria (protein:creatinine ratio of ≥0.3 
and/or dipstick reading > +1) was applied (Marchand et al., 2016). 
 
China 
Prevalence of preeclampsia in China may account for approximately 5 – 7% of all 
pregnancies (Li et al., 2018; Liang et al., 2019), although there have been very few studies to 
date that focus on the specific rate of preeclampsia throughout China. Additionally, those that 
have, predominantly include proteinuria alongside new onset of hypertension ≥ 20 weeks’ 
gestation as a requisite for diagnosis. 
A retrospective analysis study conducted between January 2002 to December 2011 in 
the Yulin Shaanxi Province of China collected data from three large tertiary hospitals 
(involving 62,925 women who had given birth after 20 weeks’ gestation) reported an overall 
preeclampsia rate of 1.92% amongst the nulliparous, ethnic Han Chinese population, when 
compared with resident Caucasian women; suggesting Chinese ethnicity may attribute to 
lower risk for developing preeclampsia (Xiao et al., 2014). The study, however, did include 





A 2011 survey on hypertensive disorders in pregnancy (HDP) involving 112,386 
pregnant women across 38 secondary and tertiary hospitals in Mainland China found an 
overall prevalence of 5.22%; of which mild preeclampsia accounted for 15.13%, severe 
preeclampsia 39.96%, and eclampsia 0.89% (Ye et al., 2014). There were however, 
significant differences between the various geographical regions, with North China provinces 
showing the highest incidence of HDP and Central China the lowest (Ye et al.), meaning that 
further exploration of these geographic differences (aside from noted risk factors including 
nulliparity, multiple pregnancy, age of >35 years, obesity, history of hypertension and 
diabetes) is warranted. 
In a large population-based study involving 205,605 singleton pregnant women 
undertaken in two Southern Chinese provinces between October 1993 and September 1995, 
the overall incidence of preeclampsia was reported as 2.4% (Liu et al., 2019). However, due 
to the period in which data was included, diagnosis for preeclampsia drew upon the now-
outdated requirement for evidence of concurrent 1+ of proteinuria on dipstick screening 
alongside hypertension ≥20 weeks’ gestation, meaning likelihood of under-reporting may be 
suspected. Further exploration of incidence of preeclampsia in China is therefore now 
warranted and overdue. 
 
India 
In India, preeclampsia may affect as many as 6 – 10% of all pregnancies although 
current data to support this remains insufficient (Khanapurkar et al., 2016; Rana et al., 2020). 
According to the 2005-2006 nationwide Indian National Family Health Survey, 
incidence of preeclampsia and eclampsia (based on self-reported symptoms from women who 
had a live birth in the five years preceding survey publication), incidence of preeclampsia 
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was estimated to be as high as 28%. Additionally, India reports the highest number of pre-
term births (<37 weeks’ gestation) in the world, with 36% of those attributed directly to 
preeclampsia (Malik et al., 2019). 
A retrospective comparative study of 208 women diagnosed with preeclampsia 
between January 2014 and December 2016 in Tamil Nadu (Kelambakkam region of India) 
reported an overall preeclampsia rate of 6.3%, but included proteinuria (≥300mg/24 hours or 
≥1+ on dipstick urinalysis) as part of the diagnostic inclusion criteria (Shankar et al., 2019). 
Additionally, a prospective observational study involving 184 women recruited 
between 13 and 18-weeks’ gestation with uncomplicated, normotensive, singleton 
pregnancies in the Tata Main Hospital in Jamshedpur in India, 14.67% went onto develop 
gestational hypertension ≥ 20 weeks of pregnancy with 22.22% of these diagnosed with 
preeclampsia. However, diagnostic criteria for defining preeclampsia was not included and 




A study of 212,463 South Korean primiparous women with no previous history of 
hypertension who birthed between January 2011 and December 2012 reported a 3.1% overall 
incidence of preeclampsia. Additionally, rates of preeclampsia were found to be as high as 
7.3% in those women diagnosed with metabolic syndrome prior to becoming pregnant (1.2% 






According to the most recent Japanese diagnostic criteria for hypertension disorders 
in pregnancy, preeclampsia is defined as new-onset hypertension from 20 weeks’ gestation 
with evidence of one or more other maternal complications (including liver dysfunction, 
neuropathy including cerebral stroke, and evidence of placental dysfunction, such as IUGR 
and stillbirth, with or without fetal anomalies) following on from manifestation of proteinuria 
(Watanabe et al., 2018, as cited in Morikawa et al., 2020). Overall incidence of preeclampsia 
in the greater Western Pacific region (which includes Japan) is estimated at 4.2%, the highest 
of all middle to high-income global populations (Nwanodi, 2016). 
 
Thailand 
A 2018 retrospective descriptive study conducted in one north-eastern tertiary care 
facility in Thailand (involving 11,199 deliveries between January 2012 and December 2016) 
identified a specific regional 1.9% preeclampsia incidence when applying revised 2013 
ACOG guidelines, which required proteinuria as part of their inclusion criteria but not fetal 
growth restriction (Kongwattanakul et al., 2018). Incidence in Thailand has previously been 
reported as high as 4.7% (Pitakkarnkul et al., 2011, as cited in Kharaghani et al., 2016) while 
rates between 2002 – 2012 were cited at 2.2%. Authors of the more recent 2018 study 
recognised, however, that revision of the 2013 ACOG diagnostic criteria could potentially 
result in changes to incidence rates, alongside other, associated, maternal, perinatal and 
neonatal outcomes and impacts, with scope for future nation-wide research identified 






Following a nationwide study assessing data from 1,347,672 live births born between 
January 2004 and December 2011 in Taiwan, prevalence of preeclampsia was determined at 
2.27%, although definitive diagnostic criteria for preeclampsia was neither clearly defined 
nor described within the scope of the study (Yu et al., 2020). Additionally, authors decided to 
combine gestational hypertension and preeclampsia as a composite outcome, recognising that 
mild cases of preeclampsia may have been missed or inaccurately diagnosed and therefore 
incorrectly coded.  
An earlier 2018 retrospective population-based cohort study of all singleton 
pregnancies of ≥ 20 weeks’ gestation resulting in either live or stillbirth babies (n=2,884,347) 
between January 2001 and December 2014, found an incidence of 1.7%, following a rising 
trend since 2012, with a steady increase in (notably) early-onset preeclampsia but also late-
onset preeclampsia (You et al., 2018). Advanced maternal age, primiparity, stroke, diabetes, 
chronic hypertension and hyperthyroidism were all determined as risk factors for 
preeclampsia; again, criteria for diagnosis of preeclampsia was not specified (You et al.). 
 
Indonesia 
In Indonesia, preeclampsia, eclampsia, infection and bleeding account for 75 – 85% 
of all maternal deaths, with incidence of preeclampsia estimated to be between 3 – 10% of all 
pregnancies, with most recent figures citing a rate of 4.6% (Jayanti et al., 2017; Suparman et 
al., 2018; Sufriyana et al., 2020). Additionally, more recent Indonesian maternal mortality 
rates arising directly from preeclampsia are reported at 4.91% (Liwang & Bhargah, 2018). 
Between 2006 and 2008, 542 cases of preeclampsia were reported in 7285 deliveries in the 
Dr Hasan Sadikin Hospital (7.44% incidence), with an associated maternal and perinatal 
mortality rate of 0.3% and 0.21% respectively (Suparman et al.). Preeclampsia was attributed 
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to enhanced risk for both maternal, perinatal and neonatal mortality and morbidity, notably 
from placental abruption, intrauterine fetal growth restriction and preterm (often iatrogenic) 
birth (Sufriyana et al., 2020). 
_______________________________________________________ 
 
There were no other studies undertaken in either Central or South East Asia that met 
with the search criteria, although figures related to incidence in Philippines and Vietnam 
(5.6% and 1.2% respectively) were cited (but not explored) in the aforementioned 2016 
cross-sectional study undertaken in Mongolia (Marchand et al., 2016).  
Similarly, incidence in Bangladesh was also cited at 12% (Jahan et al., 2015, as cited 
in Kharaghani et al., 2016) but with no further exploration of this estimate proffered. 
In Pakistan, incidence of preeclampsia is estimated to be as high as 55.3% amongst 
obese, primigravid women, but no figures pertaining to the nation’s overall rate were 
available at the time of writing this thesis (Hussain et al., 2019).  
Finally, no evidence of reporting of either rates or incidence of preeclampsia in North 





4.2.10 Australia & the Pacific Region 
 
The greater Western Pacific region (including Australia, Japan, South Korea, New 
Zealand and Singapore) collectively reports an overall preeclampsia incidence of 4.2%, the 
highest of all middle to high-income global populations (Nwanodi, 2016). 
 
Australia 
In 2013, the incidence of preeclampsia in Australia between 2000 and 2008 was 
reported as 3.3% overall, with a decrease from 4.6% in 2000 to 2.3% in 2008 (Thornton et 
al., 2013). The study also drew upon (now outdated) diagnostic criteria for preeclampsia to 
include new onset proteinuric hypertension at ≥ 20 weeks’ gestation, meaning a more 
accurate and recent data revision and investigation is now warranted. 
The 2014 Australasian, United Kingdom and Irish Screening for Pregnancy Endpoints 
(SCOPE) international cohort study examined incidence of preeclampsia in 5573 women 
between 2004 and 2011 and found the overall rate in those countries to be 4.9%, a figure 
which cannot be applied with any vigour to any one specific country (Kenny et al., 2014, as 
cited in Schalekamp-Timmermans et al., 2016). 
 
French Polynesia 
In Tahiti, 29% of cases of neonatal prematurity (204 in total between January 2007 
and December 2011) were attributed to maternal preeclampsia (Besnard et al., 2015), yet data 







In Hawaii, a 2016 retrospective study on state-wide data for birthing outcomes 
between January 1995 and December 2013 found that incidence of preeclampsia varied 
widely between ethnicities, once confounders including age, multiple gestation, multiparity, 
chronic and pre-existing hypertension, pre-existing diabetes mellitus, obesity and smoking 
had been accounted for (Nakagawa et al., 2016). After analysing 271,569 post-delivery 
hospital discharge records, overall rates of preeclampsia ranged from 2.0% for Chinese 
women (lowest risk) to 4.6% for both Native Hawaiian and Filipino women, followed closely 
by ‘other’ Pacific Island women at 4.5%. European and Japanese women were reported at 
2.9% and 2.5% respectively, with ‘other’ Asian women reported at 2.5% and an overall 
average incidence of 3.49% (Nakagawa et al.). Again, preeclampsia diagnosis was dependent 
on onset of proteinuria alongside mid-gestational hypertension, meaning under-reporting of 




4.3 Incidence & Prevalence of Preeclampsia in 
Aotearoa/New Zealand 2010 - 2020 
 
“To date, there is limited research mapping geographical incidence of 
preeclampsia within a New Zealand context” …  
(Associate Professor Katie Groom, On Track Network Trial, Auckland, New Zealand, 
personal communication, February 20, 2020) 
___________________________________________________________ 
The rate of live births over the past ten years in Aotearoa/New Zealand has averaged 
60,308 annually. However, this rate has steadily fallen by approximately 3% per annum since 
2017, with the lowest recorded birth rate since 2005 (57,744) reported in 2020; 57,753 live 
births in 2020 compared with 59,637 the previous year (Statistics New Zealand, 2020). 
4.3.1 Live Births in Aotearoa/New Zealand 2010 - 2020 
Figure 2 
 
Live Births in Aotearoa/New Zealand, 2010 – 2020. 
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Meanwhile, research assessing the incidence and prevalence of preeclampsia in 
Aotearoa/New Zealand is extremely limited, with only very few studies available for further 
scrutiny and evaluation at the time of submitting this thesis. 
However, recently published statistics from the New Zealand National Maternity 
Collection denote a steady rise in the number of births affected by eclampsia / preeclampsia, 
increasing from 2710 documented cases in 2014, to 3251 documented cases in 2018 (see 
below, Figure 3).  






















Number of Eclampsia/Preeclampsia 
Births, New Zealand 2014 - 2018
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The following visual graph (Figure 4) denotes the regional domiciles recording the 
highest rates of eclampsia and preeclampsia within Aotearoa/New Zealand. However, data 
differentiating between the two disorders is not currently available for evaluation or 
comment. 




Areas worst afflicted with eclampsia/preeclampsia in New Zealand according to domiciliary code           




Note: This figure was created using statistics obtained from the National Maternity Collection, New Zealand 
(MoH, 2020). 
While the author recognises the value of analysing and proffering comment on all 
1700 domiciliary results for rates of preeclampsia in Aotearoa/New Zealand, this is 
acknowledged as a limitation of the aims of this research. Further and future analysis of these 












































































































































































Areas worst affl icted with eclampsia/preeclampsia 
in New Zealand according to domicil iary code 
(2014 - 2018) 
Top 54 out of 1700 results
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part of an ongoing research project. Nonetheless, emergent themes from the 54 domiciliary 
results as denoted in the graph above should be noted and commented upon: 
Of the regions reporting the highest incidence of preeclampsia in Aotearoa/New 
Zealand, there is direct correlation between that and socio-economic deprivation, whether the 
domiciliary area is urban (and therefore more highly populated), industrial, or rural. A geo-
coded map of the above data superimposed upon the reporting of socio-economic deprivation 
and quintile scales would afford greater analysis of this theme and has merit for further 
investigation. Geocoding is a scientific algorithm that enables addresses to be matched to 
specific geographic locations and is an important step in using Geographic Information 
Systems (GIS) typically to determine association between environmental exposure 
assessment and adverse health outcomes (Avanasi, et al., 2016, p. 505). Such a project would 
afford greater insight into the established links between socio-economic deprivation, 
environmental pollution and disease that current and emergent research is now determining as 
definitive causation for the pathogenesis of preeclampsia (Hutcheon et al., 2011). 
While the author could find no current New Zealand publications specifically 
assessing either incidence or prevalence of preeclampsia in Aotearoa/New Zealand, 
several journal articles and national reports and reviews were perused and are included 
below for comment: 
A 2012 New-Zealand-based prospective cohort study (Anderson et al., 2012) 
examining the impact of maternal body mass index on the phenotype of preeclampsia 
reported a higher risk for disease diagnosis and progression amongst women who were 
overweight or obese in early pregnancy. However, the study did not report on specific rates 
of prevalence or incidence of preeclampsia in Aotearoa/New Zealand. 
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In 2018, a systematic review and meta-analysis examining the efficacy of maternal 
folic acid supplementation for the prevention of preeclampsia noted that the global incidence 
of preeclampsia was estimated at approximately 4.1% with regional differences ranging from 
1 – 7% worldwide, while in New Zealand, rates of preeclampsia were approximated as 
affecting 3% of all pregnancies, with higher rates noted in nulliparous women (Bulloch et al., 
2018). 
In 2016, the Neonatal Encephalopathy Working Group (NEWG) in Wellington, New 
Zealand reviewed a series of 47 babies diagnosed with neonatal encephalopathy (NE) 
between 2013 and 2015 following an acute peripartum event; including placental abruption 
and uterine rupture, eclampsia and preeclampsia, shoulder dystocia, cord prolapse and 
emergency caesarean section. More than 13% of all cases involving NE were determined as 
attributable to maternal hypertensive disorders, including preeclampsia. In two-thirds of all 
cases of NE that were reviewed, mortality and severe morbidity outcomes were considered 
potentially avoidable (PMMRC, 2018). 
The 2018 PMMRC determined that the neonatal mortality rate has not reduced in 
New Zealand in the past decade when compared with other comparable countries such as the 
United Kingdom and Australia, remaining at 2.5/1000 live births in 2016. Furthermore, there 
are significantly higher death rates for babies without congenital anomalies amongst Māori, 
Pacific and Indian women, particularly those babies born to young mothers (aged under 20 
years of age) in these same ethnic groups (PMMRC, 2018). In Aotearoa/New Zealand, 
inequities in health and health determination are marked, with the burden of adverse health 
outcomes carried predominantly by Māori women, who are disproportionately and adversely 
afflicted with risk for maternal morbidity and mortality (HQSC, 2019). Additionally, social 
inequity and institutional racism was highlighted as a dominant precursor for sub-optimal 
maternal and neonatal outcomes, with findings from the report confirming the association 
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between maternal health inequalities, fetal growth restriction and socio-economic deprivation 
(PMMRC, 2018; PMMRC, 2019). 
 
The Maternal Morbidity Working Group (MMWG) Annual Report from September 
2017 to August 2018 received 468 notifications of maternal morbidity for 437 women 
between September 2017 and 31 August 2018. While the leading cause for high-dependency 
unit (HDU) and intensive care unit (ICU) admission was postpartum haemorrhage (33.9%), 
this was closely followed by hypertensive disorders of pregnancy (30.2%), including 
preeclampsia. Once again, Māori women were over-represented in the notifications of 
women admitted to an HDU or ICU when compared with non-Māori women and show that 
Māori and Pacific women in particular, face greater likelihood of poorer birth outcomes, 
perinatal and maternal morbidity and mortality (HQSC, 2019). 
 
4.4 Synthesis of Findings 
 
Global incidence and prevalence of preeclampsia has been difficult to determine in 
exact measures, due to limitations in both reporting, likelihood of internal coding errors and 
missed diagnosis due to use of conflicting diagnostic criteria and requisites. As previously 
mentioned, 64 studies from around the globe were analysed from their full-text PDF format, 
with an additional four studies perused for general interest and comment. Each study was 
evaluated for its reporting on both or either the incidence and/or prevalence of preeclampsia 
in its nation of origin with emergent themes commented on throughout. In particular (and 
despite preeclampsia diagnostic criteria revision in 2014), many studies included beyond 
2014 continued to require proteinuria for confirmation of preeclampsia diagnosis and/or did 
not report on their country’s overall rate or incidence. Furthermore, many studies that went 
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on to re-examine previous reported rates of preeclampsia in line with the 2014 ISSHP and 
2015 SOMANZ revisions, either noted and/or were suggestive of higher rates of the disorder, 
once new criteria were applied.  
There were no studies emanating from New Zealand that resulted from any of the key 
word searches undertaken, meaning further exploration of emergent themes pertaining to the 
influence of environmental, geographic, genetic and social factors on preeclampsia incidence 




Chapter Four has explored and further evaluated each of the included review literature 
to examine and critique the incidence and prevalence of preeclampsia both globally and 
within an Aotearoa/New Zealand framework. This chapter has also drawn attention to 
significant research deficits in this field of study and provided comment upon emergent 
themes of interest that will bear impact upon future research opportunities. Chapter Five will 
now examine and discuss the implications of the research findings, conclusions and 
indications for future research pathways. 
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CHAPTER FIVE – REVIEW FINDINGS 





Chapter Five will briefly summarise the main findings of the integrative review, 
provide discussion on emergent themes and limitations captured during the review process, 
discuss key conclusions drawn by the research and provide advice regarding implications for 
future research opportunities.  
5.2 Discussion 
 
This research has sought to critique and evaluate all literature meeting with the 
study’s inclusion and search criteria, in order to: 
1) investigate the incidence and prevalence of preeclampsia both globally and within 
Aotearoa/New Zealand and 
2) identify any environmental, cultural and socio-economic factors that may be 
associated with preeclampsia incidence and prevalence in Aotearoa/New Zealand  
This evaluation has been necessary to determine feasibility for ongoing research into the 
impact of environmental factors alongside geographical, cultural and socio-economic 




Preeclampsia, a sub-set of hypertensive disorders diagnosed during pregnancy, is a 
complex pregnancy-induced syndrome occurring 20 weeks’ gestation. Preeclampsia and 
eclampsia account for one- third of severe maternal morbidities and, collectively, are 
responsible for 10–15% of maternal mortality rates in low to middle- income countries and 
30– 35% of pre-term births worldwide. (Duley, 2009). While the exact pathogenesis of 
preeclampsia remains unclear, multiple studies suggest aetiology may stem from a 
combination of several complex, multifactorial interactions; including genetic and 
environmental considerations (Zhou et al., 2019). 
Genetic and epigenetic factors including life-style considerations such as obesity, age, 
nutrition and pre-existing chronic hypertension all play an important role in the development 
and pathophysiology of preeclampsia. Moreover, geographical location, altitude, pollution 
and exposure to environmental toxins are now becoming more commonly recognised as 
significant yet potentially modifiable risks. Many of the smaller and larger scale Chinese 
studies assessed during the undertaking of the research report genetic factors associated with 
risk for preeclampsia, although incidence amongst the different populations and ethnicities is 
yet to be fully explored (Zhou et al., 2019). Additionally, known causes and risks for 
preeclampsia (aside from genetic and lifestyle factors) have been evaluated to include 
immunologic processes, socio-economic and environmental factors (Engjom et al., 2018).  
However, given that many studies perused for the purpose of writing this research 
provided no definition of preeclampsia, both reporting of incidence as well as reliability of 
data cannot necessarily be relied upon as suitably robust. Additionally, and despite a century 
of inquiry, the exact pathogenesis of preeclampsia remains largely undetermined. However, 
emerging research now seems to implicate either ‘placental’ or ‘maternal’ causes as two key 
culprits (Redmann & Sargent, 2005 as cited in Brennan et al., 2013; Robillard, 2017; 
Robillard et al., 2018).  
100 
 
Given these two causes were considered neither in the 2013 global and regional 
investigation (Abalos et al., 2013), nor within the literature commented on throughout the 
course of this thesis, no meaningful findings pertaining to the onset of preeclampsia or the 
differentiation between early and late-onset preeclampsia could be extrapolated. Furthermore, 
the difference between these two variants is yet to be applied to global and national reporting 
on the incidence and prevalence of preeclampsia. Considering the inherent risk for serious 
maternal and fetal morbidity and mortality arising from the timing of the onset of 
preeclampsia, this too should be considered within an Aotearoa/New Zealand context 
alongside evaluation of the significance of key emergent themes (namely environmental, 
geographic, cultural, and social considerations) when assessing rates of preeclampsia. 
 
 
5.3 Review Recommendations 
 
Given much of the information currently available regarding risk stratification and 
management of preeclampsia emanates from high-income countries and, while only limited 
research has thus far been undertaken in the geographic localities featuring the highest 
incidence of maternal mortality, there is ongoing need for further investigation (Dias et al., 
2019). This should additionally be considered within an Aotearoa/New Zealand context 
alongside determination of any environmental, geographic, cultural, and social considerations 





5.4 Review Limitations 
 
To date, and despite global revision of criteria for accurate preeclampsia diagnosis in 
2014, recent data reporting on the incidence of preeclampsia in both high and middle-income 
countries is remains extremely limited and potentially flawed due to coding inaccuracies, 
missed diagnosis and continued use of outdated diagnostic inclusion criteria.  
Furthermore, other than two studies sourced from the Ukraine, no other data from the 
former Soviet Union, modern-day Russia or North Korea has been reported or made 
academically available, meaning little can be currently inferred or commented upon regarding 
the incidence or impact of preeclampsia amongst those nations’ large and (in the case of 
Russia) ethnically-diverse populations.   
Of eleven international studies included in a 2016 meta-analysis of fetal sex-specific 
differences in gestational age at delivery alongside preeclampsia, only four included data 
from 2010 onwards, with only one including data from 2014 when international guidelines 
redefined diagnostic criteria for preeclampsia, once again indicating that global reporting to 
date has been extremely poorly captured (Schalekamp-Timmermans et al., 2017).  
Furthermore, no evidence of a nationwide study of this research aim could be 





5.5 Implications for Future Research 
 
There remain significant deficits in the exact determination of both global and 
national incidence and prevalence of preeclampsia, as well as little or no evidence of 
examination of any social and/or environmental risks, causes or assessments. Furthermore, as 
no evidence of a nationwide study of this nature within Aotearoa/New Zealand can be 
determined, the validity of future research and investigation has been proven. The author 
proposes the merit of progressing to a PhD thesis proposal, phase one of which would seek to 
firstly undertake an observational study to map the incidence of preeclampsia by domiciliary 
code/region in Aotearoa/New Zealand and determine whether there is: 
a) geographic variation in rates of preeclampsia in Aotearoa/New Zealand; 
b) variation in environmental pollution levels (specifically lead and other relevant 
toxins) according to domicile/region in Aotearoa/New Zealand; 
c) establish feasibility of any link between socio-economic deprivation and preeclampsia 
in Aotearoa/New Zealand. 
 
5.6 Conclusion  
 
Preeclampsia is a leading cause of severe maternal morbidity and mortality, with 
global rates increasing incrementally each year. Preeclampsia bears many serious social and 
economic ramifications for both the women and families impacted and the nations who 
shoulder the largest share of the financial burden and implications of the long-term health 
sequelae presented by the disorder. Worldwide, the exact incidence and prevalence of the 
disease remains largely unknown, particularly in lower and middle-income nations, including 
Aotearoa/New Zealand. Furthermore, accurate coding, reporting and diagnosis of 
preeclampsia remains suboptimal. 
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Globally, there are few studies which analyse the distinction, cause or incidence of 
early and late-onset manifestation of the disease pathology, as recommended in the revised 
2014 ISSHP criteria. More importantly, there are no such studies to date of this nature within 
an Aotearoa/New Zealand context or framework. Additionally, accurate data reporting on the 
incidence and/or prevalence of preeclampsia is sparse and extremely limited, while coding 
inaccuracies and inconsistent application of both the ISSHP, SOMANZ and Ministry of 
Health’s 2018 revised guidelines and diagnostic criteria are suspected and probable. 
Furthermore, many countries that re-evaluated their preeclampsia statistics following the 
2014 ISSHP diagnostic revisions, found the impact of the disorder to be greater than initial 
findings had suggested (Khan et al., 2020). Overall, global rates have risen since the last 
systematic review and meta-analysis was undertaken in 2013 (Abalos et al., 2013). 
Additionally, epigenetic and pro-inflammatory biological factors which determine 
increased risk for preeclampsia (and which continue to unfold as a result of a global rise in 
the incidence of diabetes mellitus and obesity) cannot be ignored. Furthermore, emergent 
evidence of the influence of environmental factors on the disease pathology, including 
pollution and geographic location, as well as ethnic and socio-economic factors (namely 
poverty and its engendered co-morbidities), bears significant influence and impact upon both 
risk for, incidence and prevalence of preeclampsia.  
In Aotearoa/New Zealand, Māori and Pacific peoples currently experience greater 
challenges in achieving improved health outcomes due to poverty, engendered discrimination 
and poor access to appropriate and culturally responsive care. Māori women have the lowest 
uptake of first trimester maternity services and are less likely to receive acceptable levels of 
care despite clinical and medical indication. Future research examining these preventable 
factors is warranted within an Aotearoa/New Zealand framework in order to better inform 
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